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Abstract
Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad 
of indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention 
as vectors for RNAi due to their potential advantages, including improved safety, high 
delivery efficiency and economic feasibility. However, the complex natural process of 
RNAi and the susceptible nature of oligonucleotides render the NPs subject to particular 
design principles and requirements for practical fabrication. Here, we summarize the 
requirements and obstacles for fabricating non-viral nano-vectors for efficient RNAi. 
To address the delivery challenges, we discuss practical guidelines for materials 
selection and NP synthesis in order to maximize RNA encapsulation efficiency and 
protection against degradation, and to facilitate the cytosolic release of oligonucleotides. 
The current status of clinical translation of RNAi-based therapies and further 
perspectives for reducing the potential side effects are also reviewed.  
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1. Introduction
At the forefront of medicine, gene therapy is one of the most exciting therapeutic 
armamentarium developed during the past decade. U.S. Food & Drug Administration 
(FDA) defines gene therapy as a process of replacing a disease-causing gene with a 
healthy copy of the gene, inactivating a disease-causing gene that is not functioning 
properly or by introducing a new or modified gene into the body to help treat a particular 
disease [1]. The categories potentially leading to three general modalities for gene 
therapy are: (1) gene addition, where the nontoxic functional gene is transferred into 
human somatic or germline cells, and the process is usually achieved via vectors, such 
as, retroviruses and adeno-associated viruses capable of undergoing reverse 
transcription and deoxyribocucleic acid (DNA) integration but lacking replication 
potential; (2) gene edition, where a nuclease-induced double-stranded break is occurred 
on target DNA, followed by efficient creation of variable length insertion or deletion 
mutations at the break site – tools including early stages zinc finger nucleases, 
meganucleases and the sequentially discovered clustered regularly interspaced short 
palindromic repeat (CRISPR)–CRISPR associated 9 (Cas9) nucleases can be efficiently 
programmed to cleave DNA at sites of interest; and (3) gene intervention, where the 
target gene expression or translation is inhibited or sequestered by cognate genes. Gene 
intervention is a post-transcriptional gene silencing process, which is usually achieved 
by ribonucleic acid (RNA) interference (RNAi). 
RNAi in mammalian cells is firstly demonstrated by Elbashir et al. in 2001 [2], in which 
they showed the RNAi in mammalian cells is initiated by double-stranded RNA 
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(dsRNA) with homologous sequence to the silenced gene. This finding suggested that 
comparing to other two modalities, RNAi is more straightforward as the targeted 
silencing is governed via the specificity of Watson-Crick base pairing interactions. The 
ensuing advantage is a more broad application scenario, as the translation repression 
strategy is theoretically suitable for all types of gene-related diseases. Thus, efforts are 
sequentially made to develop corresponding delivery vehicles for RNAi, and 
comparing to viral-based vectors, non-viral vehicles have drawn increasing attention 
due to some favorable characters, including retained immunostimulatory effects, lack 
of risk for mutagenic events, feasible for extra modification, and potentially increased 
targeting capability and relatively low costs [3]. Thus, exploring non-viral materials as 
RNAi vectors has been extensively investigated in the pharmaceutical field.
However, different from fabricating delivery systems for other drugs (e.g., small 
molecules, peptides, and proteins), the vulnerability of RNA and meticulous RNAi 
process in cells render particular requirements for vehicles design and fabrication [4]. 
Therefore, in this review, we summarize the general principles for the design of RNAi 
vectors, discuss the practical issues that should be considered during these vectors 
fabrication, the critical aspects of the vehicle that affects the RNA encapsulation, 
targeting yield and successful cytosolic release of RNA, and finally reviewing recent 
advances in RNAi vectors and their further perspectives for resolving the therapeutic 
obstacles and promoting the clinical translations.
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2. General requirements for the delivery systems
In this section, we will briefly discuss the major modalities of RNAi and the detailed 
biological process for RNAi. Here, we aim to illustrate the RNAi’s subcellular sites of 
function, time of function, dosage of function and form of function, which are 
indispensable for understanding the basic requirements and potential challenges for 
RNAi vector fabrication.
2.1. Natural process and the gene silencing mechanism of RNAi
The dsRNA is thought to be the initiator for RNAi, as firstly purposed by Fire et al. in 
1998 [5]. In eukaryotic cells, dsRNAs exert the RNAi function by being sequentially 
processed into: (1) short interfering RNAs (siRNAs), which may recognize the 
targeting messenger RNA (mRNA) through complementary sequence and further guide 
cleavage of targeting mRNA; or (2) microRNAs (miRNAs), which mediate 
translational repression or cleavage of mRNA targets [2, 6]. Despite the initiator 
function of dsRNAs, delivering dsRNAs for RNAi may not be applicable for 
mammalian systems, as dsRNAs are strong interferon pathway agonists, promoting the 
activation of the nuclear factor κB, and both synthetic and viral dsRNAs were shown 
to potentially lead to cell death [7].
The dsRNA is produced by two main routines: (1) RNA-templated RNA 
polymerization process with the assistant from RNA-dependent RNA polymerase 
(RdRP); or (2) by through the overlapping transcripts to achieve RNA hybridization 
[6], whereas primary miRNA (pri-miRNA), also a type of dsRNA, is processed in 
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nucleus and transported to cytoplasm by nuclear export receptor, exportin-5 [6]. Once 
the dsRNA is formed or transported in the cytoplasm, it will be processed by dsRNA-
specific RNase-III-type endonucleases, or Dicer, which contain catalytic RNase III and 
dsRNA-binding domains (dsRBDs) [8]. dsRNA or miRNA precursor (pre-miRNA) is 
further cleaved into short segments miRNA/siRNA (typically about 21–25 nucleotides 
in length) by Dicer monomer [9]. Two complementary single-strand RNA segments are 
produced from Dicer cleavage, but only one (termed as guide strand) is integrated with 
Argonaute (Ago) protein [10]. Afterwards, the rearrangement of miRNA/siRNA-
duplex-containing ribonucleoprotein particles (RNP) is initiated to form into RNA 
induced silencing complex (RISC) [11]. After forming into RISC, the single-stranded 
siRNA in RISC binds to the complementary target mRNA in these complexes, and 
cleaves the target mRNA with the assistance from Ago-protein family to accomplish 
the RNAi, whereas miRNA, usually featured with imperfect complementarity, will 
inhibit the mRNA translation or induce a mRNA degradation (Figure 1) [11, 12].
An alternative method for generating siRNA is through short hairpin RNA (shRNA) 
[13]. Similar to pre-miRNA hairpin structure, the double-strand like structure from 
single-stranded shRNA is generated from the intramolecular base-pairing due to its 
inverted repeats [14]. Rather than a natural process, shRNA is most often produced 
through the use of transcription vectors [15]. After transfected by plasmid DNA or 
virus-derived constructs, the primary transcript shRNA (pri-shRNA) will be processed 
and transported to the cytoplasm, followed by integrating into RISC as delineated above 
(Figure 1) [13, 15]. 
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Figure 1. Graphic scheme of RNA interference. Primary micro-RNA (pri-miRNA) and 
short hairpin RNA (shRNA) is exported to cytoplasm via exportin-5. The enzyme, 
Dicer, will cleave the miRNA precursor (pre-miRNA), shRNA, or long double-
stranded RNA (dsRNA), into microRNA (miRNA) or small interfering RNA (siRNA), 
separately. Followed by strand separation and forming into the RNA-induced silencing 
complex (RISC), the guide strand will bind to complementary mRNA sequences to 
perform the RNAi process. Figure is generated using Biorender.com.
2.2. Nanoparticles based RNAi
Apart from the natural process and the gene silencing mechanism of RNAi, for non-
viral nanoparticles (NPs) based RNA delivery, three fundamental questions are 
concomitantly proposed: (1) considering the subcellular location for RNA interference 
machinery, when and how the RNA is released from the NPs and transferred to the 
cytosol? (2) how many RNA can successfully reach to the cytosol, and what is the RNA 
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concentration threshold for accomplishing their corresponding functions? and (3) 
whether the RNA should be in a fully free form to fulfill the RNAi?
Understanding the nanoparticles (NPs) transport across the cell membrane is the pre-
requisite for answering these questions. Cellular uptake pathways of NPs can be 
roughly divided into three categories: macropinocytosis, phagocytosis, receptor 
assisted endocytosis (e.g. clathrin-mediated, clathrin-caveolin independent, caveolae-
mediated or other receptors-mediated endocytosis) [12, 16, 17]. Despite various 
internalization processes described in the literature, once taken-up, the NPs are 
entrapped by several endocytic compartments, which are sequentially named as early 
endosomes, late endosomes and lysosomes [18]. A more detailed discussion regarding 
to the physiochemical properties of each compartments will be discussed in Section 6.1. 
Generally, each compartment has a specific time window and physiochemical 
properties [19], and it is important to understand from which compartments are RNA 
released and how efficient this process can be achieved.
So far, the machinery of siRNA delivery through NPs has been the most widely 
investigated. One of the first systematic work was conducted by Zerial et al., who 
adopted siRNA containing lipid NPs (LNPs) with the size ~60 nm for analyzing the 
intracellular trafficking of siRNA [19]. To visualize the siRNA transport process, they 
labelled the siRNAs (which knockdown the expression of destabilized green 
fluorescent protein, d1-eGFP) with fluorescein Alexa Fluor 647 (siRNA-AF647) or 
gold nanocrystals (6 nm, siRNA-gold). Three types of biomarkers, Rabankyrin-5 for 
cell membrane, early endosome antigen 1 (EEA1) for early endosomes and lysosomal-
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associated membrane protein 1 (LAMP1) for lysosomes, were separately applied for 
identifying endocytic compartments from different stages of transport. Transmission 
electron microscopy (TEM) images first suggested the LNP-siRNA-gold NPs were 
mainly accumulated in the early and late endosomes but not in the lysosomes within 6 
h. Furthermore, time-lapse confocal fluorescent microscopy was applied to observe the 
release of siRNA-AF647 into the cytosol, and the results showed the number of LNPs 
containing endosomes were stable for over 12 min after they were uptake by different 
cells, suggesting the majority of siRNAs were still entrapped in the endosomes. Further 
quantitative evaluation of siRNA release efficacy was achieved by visualizing cytosolic 
siRNA-gold NPs. In line with the confocal results, an endosome release efficiency of 
1.3%, with only 250 siRNA-gold per HeLa cells was observed after 6 h NPs incubation, 
and for in vivo experiments (hepatocytes), the number was further reduced to 186 
siRNA-gold per cell (accounts for 1.7% of the overall siRNA-gold). To explore the 
siRNA intracellular escape time-window, and further understand from which 
endosomal compartment do the siRNAs escape from, the authors proposed two 
mathematical models: (1) a liner siRNA release kinetics, suggesting the release of 
siRNAs occurred at all endosomal stages under a zero-order manner; and (2) a 
sigmoidal siRNA release kinetics, suggesting siRNA is mainly released from a specific 
endosomal compartment. Quantifying the ratio of cytosolic siRNA were achieved by 
TEM through visualizing the siRNA-gold NPs, and the results showed the endosome 
escape of siRNA-gold was in a sigmoidal manner both in vitro (GFP-expressing HeLa 
cells) and in vivo (hepatocytes). Moreover, the data semi-quantitatively showed that 
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siRNA release occurred in a particular yet narrow time-window (< 30 min).
However, the major quantitative observation of the aforementioned work was achieved 
by siRNA-gold NPs, which may have distinct physiochemical properties comparing to 
pristine siRNA. Thus, a more detailed information regarding to the siRNA release 
amount and time-point is also elusive. To solve these problems, Lieberman et al. 
developed a high-dynamic-range (HDR) like confocal microscopy, which can 
maximally promote the bright/dark contrast to distinguish the cytosolic siRNA from 
the densely packed un-released siRNA in endosomes [20]. siRNA (labelled with Alexa 
Fluor 647, siRNA-AF647) was encapsulated by LNPs and the precise quantification of 
cytosolic siRNA was achieved by monitoring the fluctuation of fluorescent intensity, 
where an intra-endosome fluorescent signal increase suggests the partial LNP 
disintegration, yet an intra-endosome fluorescent signal decrease and cytosol 
fluorescent signal increase indicates the cytosolic siRNA release [20]. In this way, the 
authors found that the endosome siRNA escape was initiated at 5 min after maximal 
EEA1 expression on endosomes (early endosomes). Moreover, the endosome became 
EEA1- when the siRNA release occurred. As a biomarker for immature early endosome, 
the maximal appearance of Rab5 was 3 min earlier than cytosolic siRNA release, 
whereas Rab7+ endosome, a biomarker representing the maturation to late endosome, 
was almost coinciding with the cytosolic siRNA release. In contrast, Rab9 (late 
endosome) markers were observed simultaneously or shortly after the siRNA release, 
and LAMP1 (lysosome) markers became evident only after ~40 min post siRNA release. 
The overall duration of siRNA release only lasted for ~10 min with a burst release 
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duration for 1020 seconds. These results demonstrated a narrow yet particular time-
window for siRNAs endosome escape, and the siRNAs released from 
EEA1−Rab5+Rab7+Rab9±LAMP1– early endosomes within 5–15 min upon cell uptake 
(Figure 2).
Besides of the thoroughly delineated siRNA endosome escape time-point, the authors 
also suggested only few cytosolic copies of the siRNA (< 2000, ~ 2.5 ×10-9 pmol) are 
needed to achieve a maximal gene knockdown efficiency, which is in good line with 
previous results [19, 21]. Moreover, despite by increasing the siRNA concentration 
within the LNPs, one can linearly increase the cytosolic siRNA concentration, yet no 
significant difference was observed in terms of gene knockdown yield [20]. This may 
be mainly caused by the RISC components saturation [22, 23], and the excess siRNA 
that cannot form into RISC could potentially be degraded or excreted from the cell. 
Ultrahigh concentration of siRNA or miRNA may even conversely upregulate the gene 
expression as a result of competitive RISC binding [22, 24, 25], suggesting the 
concentration thresholds for efficient RNAi is low.
Regarding to whether siRNAs should be completely released from the NPs to fulfill the 
RNAi, Lieberman et al. suggested that free siRNA, rather than intact siRNA-LNPs, will 
perform the gene knockdown effects. It is plausible that free RNA will maximally 
perform the RNAi tasks as the steric hindrance may inhibit RNA to interact with the 
targeted genes or RISC. However, it also should be noted that siRNA conjugated or 
entangled with small molecules [26], peptides [27], proteins [28], polymers [29] or even 
NPs [30] may also exhibit gene knockdown potency. For example, Gilleron et al. 
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demonstrated that at the same siRNA concentration (20 nM), LNPs loaded with pristine 
siRNA or LNPs loaded with siRNA conjugated on gold NPs exhibited the same gene 
knockdown efficiency [19]. This is in good line with other reports, suggesting proper 
chemical conjugation, even with macromolecules or particles, may not interfere the 
RNAi efficiency [31-33]. However, chemical modification exhibits a positional effect 
on RNAi activity [34, 35], and readers may refer to more comprehensive reviews 
regarding to the chemical modification of oligonucleotides [36-38].
Overall, the previous machinery explorations of non-viral NPs based RNAi revealed 
the major challenges for the carrier design. These are: (1) NPs should provide robust 
encapsulation and protection towards pristine oligonucleotide for avoiding pre-mature 
degradation; (2) NPs with endosome escape capability are necessary as endosomal 
release is a discrete limiting step of gene knockdown; (3) NPs with responsive burst 
release manner is preferred for maximizing the cytosolic RNA delivery; however, this 
responsive release is not indispensable as only minimal oligonucleotide copied may 
achieve efficient RNAi; and (4) considering the ultrahigh sensitivity for RNAi, proper 
and precise targeting of the nanocarrier may reduce the off-target RNAi induced side 
effects. Therefore, in the following sections, we will sequentially highlight these four 
aspects by illustrating the principle of design of the NPs’ fabrication process for RNAi 
intracellular delivery.
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Figure 2. Endosome maturation process and the corresponding time window for siRNA 
endosome escape. After the primary endocytic vesicles formation, the NPs containing 
vesicles sequentially form into early endosomes (EE) featured with Rab5+. EEs are 
moving in perinuclear space along microtubules (MT), where the conversion of Rab5+ 
EE to Rab7+ EE take places. The endosome escape of siRNA will be initiated just before 
nascent late endosome (LE, Rab9+) undergo homotypic fusion reaction with 
Rab5+Rab7+ EE, where the majority of siRNA will be released within 10-20 seconds. 
The unreleased siRNA will accumulate in LE and lysosome (LAMP1+) for degradation. 
Reproduced and modified with permissions from ref. [39]; Copyright  2011, John 
Wiley & Sons.
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3. NPs synthesis conditions affecting the RNA stability
During the NPs’ synthesis, factors liks pH values, organic solvents, salt/metal ions and 
most importantly, the potentially existed ribonuclease (RNase), may potently affect the 
stability of RNAs and the efficiency of RNAi. Therefore, prior to introducing the 
specific design principles of NPs, we will first discuss about the influence of the 
commonly applied NPs’ synthesizing conditions on the stability of RNA.
3.1 RNase
RNase free environment is a particular requirement for synthesizing RNAi NPs. 
However, maintaining RNase-free condition is a vexing challenge not only because the 
universal existence of RNase, but also due to its ultra-stability. Common ways to 
remove enzymes, such as metal chelation, autoclaving, boiling or UV irradiation cannot 
fully deactivate RNase [40-43]. The commercialized RNase inhibitors are usually not 
broad-spectrum RNase inhibitor but rather inactivating certain RNases, and usually a 
reducing condition by adding at least 1 mM of dithiothreitol (DTT) is required [42]. 
Trivial steps during the NPs synthesis will make the situation more pernicious, therefore 
the best way to keep an RNase-free environment during NPs synthesis should be 
removing the RNase at the first step.
The de-RNase of containers (e.g., beakers and vials) for NPs synthesis can be achieved 
by baking the glassware in 200 ℃ (or higher) for at least 4 h [42, 44]. Although some 
reports suggest treating the glassware with 0.010.1% of diethyl pyrocarbonate (DEPC) 
at room temperature or 37 ℃ for overnight, further autoclave the container to remove 
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the residue DEPC [45, 46], yet, other sources indicate an incomplete DEPC 
decomposing by autoclaving, and the remaining DEPC will react with adenosine 
residues in the RNA to interfere the RNA stability [42, 47]. Therefore, for thermal 
tolerant materials, such as glassware or metal spatula, high temperature baking is the 
most convenient method. For plastics, de-RNase can be achieved by immersing the 
items with 0.1% of DEPC for overnight at room temperature. After rinsing the items 
several times with RNase free H2O, autoclaving them for 15 min at 15 psi (1.05 kg/cm2) 
on liquid cycle [48]. For microfluidic chips, which are also commonly applied for RNAi 
NPs fabrication, no detailed description regarding to the de-RNase process for 
microfluidic chip has been reported, but it has been shown that washing the microfluidic 
channel and equipment with DEPC water [49], the sequential removal of DEPC may 
be achieved by constant RNase-free water, N-2-hydroxyethylpiperazine-N-2-ethane 
sulfonic acid (HEPES) buffer or tris-(hydroxymethyl) aminomethane (Tris) buffer 
rinsing due to the DEPC hydrolysis [48]. Amine or amine derivative based buffer (e.g., 
HEPES and Tris buffer) will accelerate the DPEC hydrolysis, but it should be noted 
that the hydrolysis product, urethane, is a potent carcinogen, which needs further 
caution.
The solutions should be prepared with RNase-free water, and the organic solvent should 
be prepared via filtering through disposable ultrafiltration membrane [50, 51], as RNase 
may be more stable under neat organic solvent [52], and papers have suggested the 
effectiveness of ultrafiltration to avoid RNase contamination [51]. If possible, the 
solutions should be prepared as high concentrated stock solutions and be kept at 20 ℃ 
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[44]. All the solutions cannot be used for long time, therefore it is suggested their 
storing in small aliquots, and discard each aliquot after use [42, 44].
3.2. pH-Values
The pH value is in specific importance for NPs synthesis, as the fabrication process of 
some NPs, e.g. chitosan (CS) or ionizable lipid [53-55], will involve pH-value changes. 
Comparing to DNA linkages, RNA linkages have shown to be on average ~100,000-
fold less stable under physiological condition [56]. This is mainly because of the ribose 
sugar difference between DNA and RNA. Instead of the deoxyribose found in DNA 
(2’-hydride), ribonucleotides is composed by pentose sugar ribose (2’-hydroxyl group, 
Figure 3). The 2’-hydroxyl group is in favor of the nucleophilic attack, where a 
transesterification will take place upon the deprotonated 2’-oxygen attacking the 
adjacent 3’-phosphorus center [57, 58]. As a result, the 3’-5’ phosphodiester bonds are 
cleaved to produce fragments containing 2’,3’-cyclic phosphate and 5’-hydroxyl 
termini (Figure 3) [59, 60]. Thus, most of the RNA is not stable in alkaline pH-value 
due to the 2’-hydroxyl group deprotonation. However, experimental data suggested 
RNA hydrolysis can be both catalyzed by acidic and basic buffers [58, 59, 61]. For 
example, the 3’-5’ phosphodiester bonds cleavage and/or isomerization in acetic acid 
buffers (acetate/acetic acid) showed a buffer concentration dependent manner in a 
second-order kinetics [61]. The major catalytic activity was contributed by buffered 
acid, whereas non-buffer H+ species made minor contribution to the catalytic activity 
[61]. The mechanism for this reaction involves the hydrogen bond formation between 
acetic acid and phosphodiester, and the protonated phosphoryl oxygen is attacked by 
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the 2’-hydroxyl group with acetate functioning as catalyst (Figure 3) [61]. A detailed 
pH stability study was conducted by Lönnberg et al., who investigated the hydrolysis 
profile of 2’- Uracil RNA (3’-5’ UpU) under different pH-values at the temperature of 
363 K, and the pH was adjusted by adding hydrogen chloride or sodium hydroxide in 
acetic acid (0.045 mM)/sodium acetate (0.015 mM) buffer [62]. Results demonstrated 
that the major RNA hydrolysis was observed at the pH < 3 or pH > 7, suggesting RNA 
is still overall more stable in acidic-neutral like conditions compared to alkaline 
solutions. 
Figure 3. Chemical scheme of the RNA hydrolysis. RNA can be hydrolyzed under both 
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(A) alkaline and (B) acidic conditions. However, acid catalyzed RNA hydrolysis is 
mainly observed under acidic buffer instead of plain acid solution.
3.3. Organic solvents
A variety of NPs fabrication methods (e.g., nanoprecipitation, single/double emulsion 
and micellization) will inevitably involve organic solvents, and the solvents choice has 
impact on the RNA stability as RNA secondary and tertiary structure are governed by 
the RNA sequence-dependent interaction, including base stacking, hydrophobic 
bonding and hydrogen bonding, whereas the strength of these interactions is solvent-
dependent. RNA denaturation by organic solvents have long been observed [63, 64], 
however, there are also reports suggesting proper solvents choice may protect RNA 
from degradation [65-67]. Table 1 briefly summarizes the effects of commonly used 
organic solvents on RNA’s stability, which may provide guidance for readers to choose 
the solvent systems. Table 1 is divided into two categories, separately delineating the 
effects of organic solvent on the stability/integrity of RNA and the effects of organic 
solvents on the function of RNAi.
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Table I. Commonly used organic solvents for RNA-encapsulated NPs fabrication and 







Effects of the organic solvent on the stability/integrity of RNA
MeOH 0%-25% 58-nucleotide 
ribosomal RNA 
(rRNA) fragment
Addition of MeOH stabilizes tertiary 
structure of the RNA linearly correlated with 
methanol percentages
[67]
EtOH 96%-100% Total RNA, 
mRNA
Storage under 70 ℃  for several month 
showed no RNA degradation
[65, 66, 
68]
EtOH 100% Total RNA Some RNA with small segments failed in 
producing RT-PCR products, of note, this 
phenomenon is dependent on the source of 
RNA
[69, 70]
FA 100% Total RNA Formamide protect RNA against RNase 
catalyzed degradation
[71]






Major denaturation of RNA was observed in 









duplex which is 
the substrate of 
hammerhead 
ribozyme
The doublehelical structure of the RNA 
duplex remained stable as confirmed by the 
maintained circular dichroism spectrum of 
the RNA
[72]
Effects of organic solvents on functions of RNAi
Acetone 83% siRNA Preserved RNAi efficiency from siRNA in 
co-solvent
[73]
ACN 9% siRNA Preserved RNAi efficiency from siRNA in 
co-solvent
[74]
Chloroform 90% siRNA Preserved RNAi efficiency from siRNA in 
single emulsion
[75]
EtOH 22.5%-25% siRNA, sgRNA, 
mRNA




MeOH 5%-34% siRNA Preserved RNAi efficiency from siRNA in 
co-solvent
[80, 81]




EA 83% siRNA Preserved RNAi efficiency from siRNA in 
single emulsion
[83, 84]






83% THF, 16%; 
MeOH, 45%; 
chloroform, 22%
siRNA Preserved RNAi efficiency from siRNA in 
co-solvent
[86]
aPercentages indicate the volumetric percentage of organic solvent in the organic solvent/water co-
solvent. ACN, acetonitrile; DCM, dichloromethane; DMSO, dimethyl sulfoxide; DMF, 
dimethylformamide; EA, ethyl acetate; EtOH, ethanol; THF, tetrahydrofuran; FA, formamide; MeOH, 
methanol.
3.3. Salt and metal ions
Various aqueous buffers are usually involved in the NPs’ production. However, the 
choice of the buffer may also hinder the stability and integrity of RNAs. Metal ions can 
induce the degradation of RNA under certain conditions, and RNAs are much more 
vulnerable than DNAs. At the zinc concentration of two Zn2+/nucleotide, about 5000 
breaks occur in adenine-containing polyribonucleotides (Poly(rA)) strand for one break 
in a DNA strand [87]. It should be noted that not all metal-binding events trigger RNA 
hydrolysis, and for long RNA strand, metal ion binding is even indispensable for 
preserving the function of RNA by inducing the RNA folding into stable tertiary 
structures [88, 89]. However, this is not the case for oligonucleotides that typically 
contain ~30 nucleotides. The accelerated RNA cleavage is mainly observed in divalent 
metal ions and some lanthanide ions, and the mechanism is similar to alkaline induced 
RNA hydrolysis, as described above (Figure 3) [42, 90], where the metal hydrate will 
interact with the phosphate oxygen, sequentially abstracting the proton from 2’-
21
hydroxyl group to induce the phosphate rearrangement [91]. Therefore, the metal 
hydrates with low pKa value exhibit higher RNA cleavage efficiency [91, 92]. This is 
consistent with the results from investigating metal ions induced scission of 
oligonucleotides bearing an acridine [92], where RNA scission efficiency from 
different metal ions is: La3+ ≥ Eu3+ ≥ Lu3+ > Zn2+ ≥ Mg2+ ≥ Ca2+ > Mn2+ > 
Co2+ > Cu2+ > Ni2+; Na+ and K+ showed no obvious effect on RNA hydrolysis. 
Therefore, it is preferred to apply de-ionized water for preparing RNA solution, and to 
avoid metal ion catalyzed RNA scission, 0.1–1 mM of ethylenediaminetetraacetic acid 
(EDTA) can be applied for chelating potential metal contamination [42]. Other specific 
chelators, such as trinitriloacetate (TNA, for Zn2+) or 
ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA, for Ca2+), can also be applied 
based on the NPs synthesizing condition [42]. 
4. RNA encapsulation
The choice of proper materials to formulate and effectively encapsulate RNAs, and 
protect them from degradation is the foremost step for RNAi nanosystem fabrication. 
In this section, we discuss the general methodologies to formulate nanosystems for 
RNA encapsulation, a potential mechanism for effective RNA protection and 
encapsulation, and identify and describe parameters which play a key role in 
encapsulation efficiency and vehicle stability.
To identify recent changes in the materials used for RNAi nanosystem fabrication, we 
implemented a query on the retrievals “nano” + “RNA interfering”, using Scopus 
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Search application programming interface (API) in R software 
(https://github.com/christopherBelter/scopusAPI) [93]. After extracting the keywords 
from the 200 most relevant scientific articles (sorted by their number of citations), we 
manually cleaned the data and selected all relevant words associated with biomaterials 
that appeared in the database. The results suggest changes over time of most commonly 
applied biomaterials for RNA encapsulation. Figure 4 (left: bar plot, right: word cloud) 
provides an illustrative comparison of the frequency of the most relevant words 
associated with materials for two investigated periods (20162018 and 20192021). 
Figure 4. Visualization of the most frequent words related to the materials from 
keywords of scientific papers using Scopus Search “Nano” + “RNA interference” over 
two the periods 20152018 and 20192021. 
4.1. Lipid-based NPs
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Lipid-based NPs (LNPs) have been used to deliver various drug substances, including 
therapeutic RNAs [53, 54, 94, 95]. The majority of the fabricated LNPs consist of four 
main components that include an ionizable lipid, a phospholipid (e.g., 1,2-distearoyl-
sn-glycero-3-phosphocholine, DSPC), cholesterol, and a poly(ethylene glycol)-
conjugated lipid (PEG-lipid) [53]. The ionizable lipid, which is positively charged at 
low pH-values, allows the binding with the negatively charged RNA through 
electrostatic interactions. This ionization is also responsible for the RNA release inside 
endosomal compartments due to the low pH-derived protonation (pH ~ 5) [96], and a 
more detailed discussion regarding to the design of lipid for facilitating endosome 
escape will be presented in Section 6.4, whereas in this section we will mainly focus on 
delineating the mechanism and methodologies of RNA encapsulation by LNPs. One 
major advantages for LNPs is the simplicity of manufacturing – LNPs are usually 
prepared in a rather straightforward method. They can be both produced through the 
most basic bulk method, such as static mixing or pipet mixing [97-99], that is the lipid 
compositions are dissolved in water miscible organic solvents like ethanol or acetone, 
whereas the RNAs are dissolved in aqueous solution. Rapid mixing is then used for 
spontaneous formation of the RNAs containing LNPs. LNPs can be dialyzed in aqueous 
buffer (such as PBS) to remove the organic solvent and free RNAs, and the yielded 
product are diluted in aqueous buffer to achieve the desired final RNA concentration. 
Microfluidic methods have also been widely applied in RNAs containing LNPs 
fabrication due to its advantages in reducing the mixing time and batch-to-batch 
variation [76, 100, 101]. A proper control over the flow rate, flow ratio with the 
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microfluidic technology can also avoid post-treatment like in bulk methods, such as 
dialysis or direct dilution [76]. 
The effective protection from LNPs towards the encapsulated RNAs is generated from 
the structure of LNPs. The phospholipid and cholesterol are essential for the lipid 
structure, which may provide preliminary protection towards the encapsulated RNAs 
[102], where the PEG-lipid shields the RNA from degradation, while providing in 
tandem colloidal stability and stealth properties [102]. Leung et al. elaborated the 
potential mechanism of the RNAs encapsulation process by LNPs [103]. The cryo-
TEM images of a typical siRNA containing LNPs (constituted by 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC), cholesterol and an ionizable cationic lipid 
DLinKC2-DMA) showed that, in contrast with bilayer vesicle nanosystems, LNPs 
showed an electron-condensed core, which is further confirmed to be the encapsulated 
siRNA complexed composed by siRNA, cationic lipid and the cholesterol. Along with 
the increasing siRNA concentration, more cationic lipid will be transferred from 
external lipid monolayer to the cavity to form into complex with siRNA, and this 
lipid/siRNA complex renders effective protection towards siRNA. Sequential 
molecular modelling demonstrated that an aqueous compartment inside of the LNPs 
cavity, this periodic structure is composed by nucleic acids and the polar moiety of the 
lipid, which is further surrounded by cholesterol (Figure 5A), whereas the PEG layer 
was consistently presented in the outer layer to provide further shielding and protection. 
However, a different RNAs packing model was recently proposed by Kulkarni et al., 
who investigated the LNPs morphology changes during the siRNAs encapsulation 
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process with pH changes [104]. An improved cryo-TEM instrument with higher 
acceleration voltages (300 kV) and better detection was adopted for improving sample 
penetration to better image the LNPs core. The authors suggested a more detailed 
description regarding to the siRNA encapsulation process, which is initiated by the 
formation of small vesicles that contain siRNA between closely apposed lipid 
monolayers at lower pH value, under which the ionizable lipids are protonized to be 
cationic. With increased pH-value, the deprotonation of ionizable lipids will facilitate 
fusion of these small vesicles due to the reduced inter-vesicle electrostatic repulsion. 
Along with this process, siRNA is packed into a closely apposed lipid bilayer, which 
will further sandwiching the siRNA and segregate it from the outer layer of LNPs, and 
this process eventually halted by the phase separation of PEG-lipid (Figure 5B). This 
observation is consistent with a more recent study by the same group [98], where they 
showed the gradual absence of the amorphous solid lipid core with increasing siRNA 
loading concentration (Nitrogen/phosphorous ratio, N/P, decreasing from 3 to 1), 
indicated the encapsulation of siRNA converts associated ionizable lipid into a form of 
siRNA/lipid/cholesterol complex. It should be noted that, different from previous 
molecular-modelling results [103], these findings suggested the encapsulated siRNA 
will not disperse in a “currant bun” pattern inside of the LNPs (Figure 5A), but rather 
densely packed by the lipid bilayer, and at high N/P ratio, the redundant lipids will be 
enriched in the cavity center in amorphous oil-phase like state. 
Overall, these studies suggest that the potential mechanism for the RNAs encapsulation 
and protection by LNPs is due to the RNAs/ionizable cationic lipid/cholesterol complex 
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formation inside of the LNPs, where the surface lipid are transferred into the LNPs core 
along with RNAs loading.
Figure 5. (A) Molecular-modelling approach for illustrating the RNAs encapsulation 
process by LNPs. Ionizable cationic lipid is shown in yellow, cholesterol in pink, DSPC 
in gray, lipid polar moiety in cyan, PEG-lipid in violet, and nucleic acids (duplex DNA) 
in red; water not shown for clarity. (B) Different from the “currant bun” model as shown 
in (A), new model is purposed for describing the RNAs encapsulation process, where 
siRNA containing small vesicles are first formed under low pH value (pH =4). Along 
with the pH value increase, neutralized ionizable lipid start to fuse with each other and 
in the end, a “siRNA sandwich” structure is formed where siRNAs are tightly packed 
by closely apposed lipid monolayers, and the redundant lipid will accumulate in the 
cavity center in an oil-phase. Modified and reproduced with permission from (A) ref. 
[105]; Copyright  2012, American Chemical Society; and (B) ref. [104]; Copyright 
 2018, American Chemical Society.
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Considering the mechanism and process of RNA encapsulation by LNPs, 
corresponding parameters can be tailored to optimize the size, stability of LNPs and the 
encapsulation efficiency of RNAs. Formulation optimization majorly accounts for the 
satisfied physiochemical characterization of LNPs. However, conventional formulation 
optimization process is vastly dependent on phenomenological or empirical 
approaches, and further understanding of the RNAs encapsulation mechanism and 
process may provide an alternative practical guideline for promoting the LNPs 
performance. For example, considering the theoretical LNPs model established by 
previous studies [103-106], under higher N/P ratio (such as 3 or 6, which is the typical 
formulation applied clinically [107, 108]), the redundant bulk of the lipids will 
accumulate into a central oil phase [104], therefore the stability of corresponding LNPs 
may be affected by the solubility of the lipid components with one each other. Another 
example, in a typical LNPs formulation composed by ionizable cationic 
lipid/DSPC/cholesterol/PEG-lipid, the stability of the corresponding LNPs is 
dominated by the proportions of each components, especially the proportions of 
ionizable cationic lipid and cholesterol. As considering the solubility of cholesterol in 
ionizable lipid oil phase is only 8 mol-%, and an equimolar level of cholesterol is 
presented in the DSPC surface monolayer [109], with the formulation of ionizable 
lipid/DSPC/cholesterol/PEG-lipid = 50/10/38.5/1.5 (mol-%), only 14% of the total 
cholesterol can be dissolved and well dispersed in LNPs, whereas the surplus 
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cholesterol may be potentially precipitated into crystalline form and affect the stability 
of the LNPs. 
Understanding the RNAs loading process may also provide guideline for maximizing 
the encapsulation efficiency. As RNAs are densely packed by the ionizable lipid 
bilayer, which is stabilized by cholesterol, thus it is intuitively speculated that the ratio 
and contents of lipid and cholesterol may govern the RNA loading capacity of LNPs. 
Cullis et al. [98] demonstrated that with a fixed component of LNPs containing 2,2-
dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (KC2, ionizable lipid), DSPC 
(helper lipid), cholesterol and PEG-lipid, when the cholesterol proportion is lower than 
2.5 mol-%, the siRNA encapsulation efficiency is negligible (< 10%), whereas this 
number is increased to ~40% when cholesterol reaches to 10 mol-%, and the siRNA 
encapsulation efficiency is further progressively enhanced to over 80% at 20 mol-% of 
cholesterol. Simply enhancing the cationic lipid concentration (94 mol-%) showed 
reverse effects on siRNA encapsulation efficiency, confirming the stable formation of 
siRNA/ionizable lipid complex need the stabilization effects from cholesterol. Despite 
the addition of helper lipids (in the current case, DSPC) will not directly participate in 
the formation of siRNA/lipid complex [104-106, 110]; however, as we discussed above, 
due to the limited solubility of cholesterol in ionizable lipid oil-phase [104, 111], the 
addition of DSPC amplify the siRNA encapsulation efficiency by preventing crystalline 
cholesterol formation and stabilize the siRNA/lipid complex. 
The strategy by tailoring cholesterol to optimize the RNA encapsulation efficiency was 
also recently investigated by Patel et al. [112], who demonstrated the cholesterol 
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replacement with other analogs like betuline, lupeol, ursolic acid, and oleanolic acid 
significantly affects the RNAs encapsulation efficiency of LNPs. Results suggested that 
for those cholesterol analogs wherein the C-20 to C-27 tail is modified into a 5th ring 
structure (Figure 6), the RNAs encapsulation efficiency is dramatically reduced to < 
50%. This phenomenon can also be explained by the aforementioned mechanism that 
the existence of extra ring structure in the cholesterol analogs yields additional steric 
hindrance, which disturbs the regular organization of lipid component [113], and leads 
to poor encapsulation of RNAs.
Figure 6. Chemical structure of cholesterol and its corresponding analogues. The 
addition of 5th ring in cholesterol tail dramatically reduces the encapsulation efficiency 
of siRNAs. Modified and reproduced with permissions from ref. [96]; Copyright  
2020, Springer Nature.
The mechanism of RNAs encapsulation by LNPs can also be adapted in guiding and 
interpreting cationic lipid choice. Lou et al. [114] investigated the impact of the cationic 
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lipid selection on RNAs encapsulation and delivery. The authors used a variety of 
ionizable lipids, including 1,2-dioleoyl-3-trimethyl ammonium-propane (DOTAP), 
1,2-dimyristoyl-3-trimethyl ammonium-propane (DMTAP), dimethyl dioctadecyl 
ammonium (DDA) and 1,2-stearoyl-3-trimethyl ammonium-propane (DSTAP). The 
most obvious difference was observed between DOTAP and DSTAP. The only 
structural difference is that DSTAP contains two saturated aliphatic tails, while DOTAP 
contains a cis-double bond in each of its two aliphatic tails. Whereas the RNAs 
encapsulation efficiency from DSTAP based LNPs was dramatically reduced from 97% 
to 70%. Although the authors did not further elaborated the potential mechanism behind 
this phenomenon, previous studies demonstrated that the existence of double bond in 
the hydrophobic tail potentially increases the lipid fluidity, and contributed to the 
stabilization of lamellar phases of the lipid [115, 116]. This feature may further 
contribute to the maintenance the opposed bilayer structure of RNA/lipid complex, as 
such promote the encapsulation efficiency. Similar phenomenon was also observed by 
Ball et al. [97], who have noticed the increasing proportion of DOPE (contain cis-
double bond) along with decreasing the proportion of DSPC (saturated tails) 
progressively increased the encapsulation efficiency of both siRNAs and mRNAs.
4.2. Polymeric NPs
Polymer NPs constitute an alternative approach for the delivery of various 
oligonucleotides [117-119]. The precise control over their physicochemical properties 
and architecture, using bottom-up chemical approaches, provides a significant 
advantage over the lipid-based systems described above [120]. In fact, the various 
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chemistries allow for the fabrication of nanoparticles with tailor-made properties like 
control over the loading and release profiles, degradability, and stimuli-responsiveness 
[119, 121, 122]. The practical issues regarding to the particular cautions related to 
synthesizing conditions (organic solvents, pH, aqueous solutions etc.) are discussed in 
Section 3. Here, we will mainly focus on parameters which may affect the RNAs 
encapsulation by synthetic polymeric materials and the corresponding manipulating 
methods. Similarly, prior to introducing the detailed discussion regarding to the RNAs 
encapsulation and release from polymeric NPs, we first introduce the general RNAs 
encapsulation process in different polymeric materials. 
As we discussed previously, in LNPs, oligonucleotide binding is governed by two main 
contributing interactions, electrostatic and hydrophobic. The former are responsible for 
the RNA binding and indirectly control the loading efficiency, where the latter are 
responsible for nanoparticle stabilization and RNAs’ degradation protection. Evidently, 
the RNAs’ encapsulation efficiency and release profile, the degradation protection 
efficiency and the nanoparticle’s location where RNA resides in, are depending on the 
used polymer and the approach used for the nanoparticle synthesis. Hydrophobic ionic 
polymer, such as PLGA, can only encapsulate the RNA through double-emulsion 
method to load the siRNA in its interior for protecting it from exogenous factors [123], 
where a positively charged polymer will result in a more ‘exposed’ RNA binding [124]. 
In the case of a hydrophilic/hydrophobic co-polymer (Figure 7), the RNA’s residency 
and subsequently the protection efficiency will be determined by which interacting 
force prevails during nanoparticle synthesis. Finally, and as it is discussed later [125, 
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126], RNAs can also reside in the interspace of polymer brushes resulting in core-
independent oligonucleotide-delivery nanocarriers. Notably, another driving force for 
RNA binding that is not commonly used, but should be considered, is intercalation 
[127]. As Zhou et al. reported [127], the use of intercalating groups in siRNA-loaded 
nanocarriers enhances siRNA protection at physiological pH, over nanocarriers that 
present only hydrophobic groups. 
Besides the non-covalent approaches that are mainly used due to their simplicity in the 
fabrication of RNA-loaded nanoparticles, covalent binding has also been reported [128, 
129]. Although covalent binding improves stability and pharmacokinetic profiles, the 
higher complexity during nanoparticles’ formulation makes this approach less 
attractive compared to the ‘easy’ non-covalent binding.
Figure 7. RNAs encapsulation model by different materials including: (A) chitosan; (B) 
PEI; and (C) PLGA. Modified and reproduced with permissions from ref. [130]; 
Copyright  2017, Elsevier B.V.
As described above, the binding of the chosen RNA-therapeutics is mainly achieved 
through electrostatic interactions between the positively charged groups of specific 
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polymers (e.g., poly ethylene imine-PEI and poly amidoamine-PAMAM) and the 
negative charge of the oligonucleotides. Notably, the positively charged polymer amine 
groups (N = nitrogen) to the negatively charged nucleic acid phosphate groups (P) are 
among the most important physicochemical parameters determining properties like 
stability, surface charge, and size. As a result of the low charge of siRNA, high N/P 
ratios result in higher RNA complexation. However, the higher this ratio is, the higher 
the positive surface charge and the higher the toxicity. 
Therefore the optimization of N/P ratio is the preliminary step for efficient RNAs 
encapsulation, and a proper N/P ratio can improve complexation without increasing the 
cationic polymer. For example, Yu et al. [131] presented a strategy that involved the 
use of polymerized siRNA (multi-siRNA). This strategy resulted in increased charged 
density and chain flexibility in the multi-siRNA, leading to a higher complexation 
degree and improved biological stability even at a low N/P ratio. The multi-siRNA was 
complexed with PEI through a hybrid rolling circle amplification (RCA) co-carrier. As 
it was demonstrated, it could not be replaced by other high molecular weight polymers. 
Degradation studies of the PEIy-RCA18-siRNA (N/P = 2) showed no siRNA 
degradation, where the free RCA18-siRNA degraded in just thirty minutes. Different 
N/P ratios were tested, resulting in low cytotoxicity when N/P ≤ 6. However, a higher 
N/P ratio was necessary (N/P=10) for effective transfection, ranging from 24% to 58%, 
depending on the used formulation (Figure 8).
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Figure 8. Illustration of the direct complexation of naked siRNA by PEI and the 
complexation utilizing RCA product as a co-carrier for siRNA transfection. 
Reproduced with permission form ref [131]; Copyright 2019, American Chemical 
Society.
The optimized N/P ratio can also be affected by the length of RNAs. In a different study 
performed by Zhang et al. [132], PEI was conjugated with β-cyclodextrin to deliver 
single guide RNA (sgRNA). For N/P ≥ 20, all plasmids ranging from 3487 to 8506 
base pairs formed large but loose complexes with cyclodextrin. When N/P reached 60, 
all plasmids was fully condensed into nanocomplexes with the size ~200 nm. When 
higher N/P ratios were used (≥ 60), induced apoptosis was observed.
Besides of the amine density, other factors like the backbone structure of the polymer 
also affects the encapsulation and release for RNAs. Blersch et al. [133] created a 
library of light-responsive nanoparticles (160 formulations) exhibiting 
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physicochemical diversity, aiming at studying their ability to act as nucleotide-delivery 
systems for siRNAs or miRNAs. Polymers with structural diversities were produced by 
Michael-type addition chemistry, which was based on the reaction between a photo-
cleavable moiety [(2-nitro-1,3-phenylene)bis(methylene) diacrylate] with a set of 
bisacrylamide and amine monomers. Among which, only 14 types of the polymer 
exhibited siRNA encapsulation efficiency higher than 80%, and the authors suggested 
that the encapsulation efficiency of siRNA was rather not solely dependent on positive 
zeta-potential of the polymer, but also correlated to existence and type of aliphatic 
moieties in the polymer backbone. As the polymers prepared by bisacrylamide and 
amine monomers containing linear hydrophobic chains showed better chances for 
higher siRNA binding efficiency, whereas the polymers containing aromatic rings may 
interfere the siRNA encapsulation process.
It should be noted that RNAi vectors are usually composed as “hybrid materials”, where 
different type of materials are adapted simultaneously for achieving different purposes. 
For example, the biocompatible anionic polymer PLGA has been applied in 
encapsulating siRNA/cationic lipid complex to reduce the toxicity of the cationic lipids 
and further protect the siRNA from degradation with robust polymeric matrix [73]. The 
potential mechanism of LNPs encapsulation by hydrophobic PLGA was investigated 
previously by Jiang et al. [134]. Dissipative particle dynamics (DPD) simulations were 
carried out to simulate the dynamical behavior between PLGA and lipids on the 
molecular scale. As a result of the surface tension, the lipids will form into a reverse 
micelles on the surface of water. Upon the addition of PLGA, PLGA molecules will 
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shrink under the interfacial tension between PLGA and water, along with the 
encapsulated small reverse micelles fusing to one bigger micelle (Figure 9A).
Polymers can also be conjugated with other materials for efficient RNA encapsulation. 
For example, Zhang et al. conjugated PAMAM with PEG2k-DOPE and mPEG2k-
DOPE, creating mixed dendrimer micelles (MDMs) [135]. Subsequently, the MDMs 
were coated with HA-conjugated DOPE aiming at ‘hiding’ the positive charge and 
provide targeting towards CD44+ cancer cells. When HA-DOPE to MDMs ratio was 
higher than 0.5, then a negative surface charge, followed by a complete complexation, 
was observed. The HA-DOPE/MDMs prevented siMDR-1 degradation in vitro, 
improved serum stability, and demonstrated decreased cytotoxicity compared to 
PAMAM alone.
Besides of that, several studies also focus on core-independent approaches by using 
polymer brushes. Polymer brushes constitute macromolecular structures with polymer 
chains densely tethered to another polymer chain or the surface of various structures 
(e.g., NPs) through covalent or non-covalent binding [136-139]. These brushes cover 
the NPs’ core or the surface they are applied to and allow the complexation of various 
therapeutics, including RNAs in the interspace, and the size and stability can be feasibly 
tailored by manipulating the characters of NPs core [125]. Polymer brushes reduce 
protein adsorption while in parallel enhance the oligonucleotide complexation due to 
an entropic stabilization, leading to stable oligonucleotide retention.
An example of the use of polymer brushes for RNA delivery was reported by Li et al. 
[125], where poly (dimethyl amino ethyl methacrylate) (PDMAEMA) was used for the 
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delivery of oligonucleotides with 22 base pairs. The PDMAEMA polymerization 
process is initiated on the silica NPs surface, and copolymer, poly (dimethyl amino 
ethyl methacrylate-b-oligo ethylene glycol methacrylate (PDMAEMA-b-OEGMA) 
brushes can further conjugated on the NPs surface. The existence of robust silica NPs 
core could yield a better control over size and NPs stability, whereas the existence of 
dense polymer brush (0.5 polymer chain/nm2) will facilitate the RNAs encapsulation. 
The authors noticed that the polymer density increase can only enhance the 
encapsulation efficiency for the nucleic acids smaller than 100 base pairs. To further 
understand the encapsulation mechanism by such method, the authors applied surface 
plasmon resonance (SPR) chips whose surface is covered by PDMAEMA-b-OEGMA, 
then 0.5 μg oligonucleotides was injected in the chip for evaluating the interactions 
between polymer brushes and nucleic acids. The results suggested the nucleic acid 
encapsulation process is kinetically limited by molecular crowding, and the entropic 
drive for the adsorption of nucleic acids is related to the molecular size, where 
oligonucleotides (RNAs with the size of 22 base pairs) could penetrate into the core of 
the polymer brushes to show the best entropic stabilization, whereas large DNA plasmid 
are mainly anchored on the surface of polymer brush (Figure 9B-C). The main reason 
for the oligonucleotides penetration may be due to the frustrated conformation of 
polymer chains upon binding with RNAs [140], as when some hydrophobic groups of 
polymers are inserted in water molecules, the entropic effect leads to a rearrangement 
of water molecules around the non-polar groups of polymers to stabilize the structure 
[141].
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Figure 9. (A) Snapshots of DPD simulation to understand the lipids encapsulation 
process by PLGA. Water is shown in green, lipid head in red, lipid tail in yellow, and 
PLGA in magenta. (B) Quantitatively evaluation of nucleic acid encapsulation 
efficiency by brushes polymers with different polymer density. (C) Schematic 
illustration of the interaction between nucleic acid molecules with different base pair 
with PDMAEMA brushes. Reproduced with permission form (A) ref. [134]; Copyright 
 2015, Wiley-VCH; and (B-C), ref. [125]; Copyright 2018, American Chemical 
Society.
4.3. Biomacromolecules
Biomacromolecules constitute another class of material used for oligonucleotide 
delivery [142-145]. Although the term includes various sub-classes like carbohydrates, 
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proteins, and nucleic acids, due to the brevity concern, we will only focus on 
carbohydrates in this section. Among these, polysaccharides (e.g., chitosan and 
dextran) and glycosaminoglycans (e.g., hyaluronic acid) are the most studied 
carbohydrates for RNA delivery. As in lipid and polymer NPs, the various RNAs are 
complexed with the biomacromolecules through electrostatic interactions. Therefore 
the general guideline for optimizing the RNAs encapsulation also fits the principles 
described above. For example, cationic polysaccharides chitosan has long been 
investigated for oligonucleotides encapsulation, and previous studies suggested the 
molecular weight, degree of deacetylation, the chitosan salt form used, and N/P ratio 
could affect the RNA encapsulation efficiency [146, 147], however the underlying 
mechanism can be potentially attributed to the altered electrostatic interactions. For 
example, the work conducted by Holzerny et al. measured the binding thermodynamics 
between siRNAs and chitosan with different molecular weight (44 kDa, 63 kDa, 93 
kDa and 143 kDa) and deacetylation degree (ranging from 78% to 86%) [148]. The 
results suggested, albeit the different molecular weight and deacetylation degree, the 
chitosan siRNA binding enthalpies (ΔHbind) showed no significant difference among 
the tested chitosans (Figure 10), suggesting the binding type is the same for all types 
of chitosans. However, experimental molar binding stoichiometry (Nsat) was 
significantly lower than theoretical value, and this phenomenon was more obvious for 
chitosan with larger molecular weight, as the relative differences between experimental 
and calculated theoretical values between 44 kDa chitosan was only 86%, whereas this 
number reduced to 69% for 143 kDa chitosan (Figure 10). The difference can also be 
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explained as previously [149], larger chitosan with higher viscosity will hinder the 
electrostatic interactions. This phenomenon was also consistent with the saturated N/P 
ratio (N/Psat) and binding constant (kD), whose values are progressively increased with 
higher Mw and lower deacetylation degree. 
Figure 10. Representative examples of binding isotherms of interactions of chitosans 
with molecular weight (Mw) of 44 kDa (up-left), 63 kDa (up-right), 93 kDa (down-left) 
and 143 kDa (down-right) with siRNA, and the corresponding quantitative data. 
Reproduced with permission form ref [148]; Copyright  2012, Elsevier B.V.
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Practically, two parameters are mainly involved in optimizing the encapsulation 
efficiency of oligonucleotides by macromolecules. First one is the N/P ratio. Different 
from lipids based materials, where the N/P ratio is rather low. For polysaccharides, 
despite the theoretical saturated N/P ratio is around 1 [148], the actually applied N/P 
ratio usually ranges from 20 to 300 [147, 148]. As results suggested low N/P ratio will 
yield physically unstable complexes. Previous study showed that for chitosan/siRNA 
complex with the N/P ratio of 5, a severe aggregation can already be observed only 
after 15 min post complexation even under high ionic condition (150 mM NaCl) [150]. 
The RNA encapsulation efficiency and the colloidal stability will increase along with 
increased N/P ratio [147, 150]; however, this may result in a limitation in the release of 
the encapsulated RNA [151, 152]. 
The pH-value during RNAs encapsulation process also heavily impact the 
encapsulation efficiency, as their surface charge is closely dependent on the pKa value 
[153]. For example, Alameh et al. showed the effect of chitosan’s deacetylation degree, 
molecular weight, and N/P ratio on the siRNA encapsulation efficiency at two different 
pH levels. Under pH 6.5, the siRNA encapsulation efficiency was almost independent 
of any of these parameters, whereas a sharp contrast was observed under pH 8, that an 
efficient siRNA encapsulation can only be achieved with high N/P ratio, high chitosan 
molecular weight and high deacetylation degree (Figure 11) [150]. As under high pH-
value, chitosan glucosamine units become deprotonated, and their interaction with 
siRNA phosphate groups decreases to promote payload release [153]. The general pKa 
values for commonly used carbohydrates are, hyaluronic acid ~3.0 [154, 155], dextran 
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~ 6.0 to 7.1 [156, 157], and chitosan 6.4 to 6.6 [158, 159]. These values allow an optimal 
design for siRNA encapsulation/complexation since below a certain pH the elctrostatic 
interactions between the positively charged biomacromolecule and the RNA 
therapeutic are enhanced.
Figure 11. Synthesizing NPs under the pH value above the pKa shows a significant 
impact on the encapsulation efficiency of siRNA. Figures are modified and reproduced 
with the permission from ref [150]; Copyright  2018, American Chemical Society.
The complexation between anionic carbohydrates, such as dextran or hyaluronic acid, 
and oligonucleotides is challenging, and the common way to solve this issue is through 
chemical modification with cationic moieties [160, 161]. The chemical modification 
can simultaneously be achieved by on-demand linkages to further promote the release 
43
behavior of loaded RNAs. As an example, Chen et al. [162] developed acid-degradable 
dextran NPs (conjugation of dextran with amine-containing molecules through acetal 
bonds) cleaved at low pH, allowing the encapsulated siRNA to be released 
intracellularly. Similar example by Qu et al. conjugated two different molecular weight 
dextran with two other peptides creating four independent systems that were tested for 
their knockdown efficiency on Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
expression on HepG2 cells. The used peptides were composed of arginine (R) and 
lysine (K) that provided the nucleic acid binding domain, histidine (H) as the RNA 
binding moiety as well as facilitating endosome escape, and cysteine as a linker 
between dextran and short peptides [156]. These results showed that higher arginine 
content demonstrated better RNAs encapsulation as well as transfection efficiency.
4.4. Inorganic NPs
Major advantages from biocompatible inorganic NPs come from their ultrahigh 
stability and highly advanced physiochemical properties, such as electro, optical, 
thermal and magnetic capabilities, making them not only suitable for loading various 
type of cargos, but also highly efficient for imaging and diagnosis [163-165]. Different 
RNA encapsulation methods are adapted based on the morphology of inorganic NPs 
(dense, porous or hallow). For NPs with dense core, such as gold NPs or quantum dots, 
the efficient oligonucleotides loading can be achieved by simply covalent conjugation. 
Firstly proposed in 1996 [166], the most commonly applied covalent conjugation 
method is achieved by utilizing NPs with thiolated surface to stably form disulfide 
bonds with thiol-terminated synthetic RNAs, and the disulfide bonds can further be 
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cleaved by glutathione (GSH) to steadily release the RNAs [167, 168]. Besides of the 
disulfide bonds, other chemical groups such as maleimide, haloacetyl and pyridyl 
disulfide are also widely applied in NPs functionalization to form into RNAs-NPs 
conjugates [169, 170]. The RNAs loading or conjugation efficiency by this method is 
vastly dependent on the morphology of the NPs and the conjugation method. For 
example, Lei et al. demonstrated how the size of NPs affect the siRNA conjugation 
capacity [170]. Gold nanoclusters with the size of 2.6 nm exhibited near 100-fold higher 
siRNA conjugation efficiency (226 µmol siRNA per g of gold cluster) comparing to 
gold NPs with the size of 13 nm (2.62 µmol siRNA per g of gold NPs), and the authors 
attributed the difference to the smaller size induced larger specific surface area [170]. 
Besides of direct conjugation, the other commonly applied method is by modifying the 
NPs with cationic polymers, either by covalent conjugation or layer-by-layer deposition 
[167, 171], to facilitate the electrostatic binding of RNA, as we discussed in Section 
4.2.
RNAs can also feasibly resides in inorganic NPs with porous or hollow cavity (porous 
silica/silicon NPs, carbon based NPs) [164, 172-174]. However, the issue of burst 
release has emerged as a major obstacle for directly loading the RNAs in porous or 
hollow nanostructures, and the engineering strategy by creating a core/shell structure 
has been extensively investigated to solve this issue [175]. The shell formation process 
can be further roughly divided into post-shell formation, where the RNAs are first 
loaded into the porous/hollow nanostructure, and the NPs are sequentially encapsulated 
by a shell structure [165, 176]; and in-situ shell formation, where the RNAs are 
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simultaneously co-encapsulated along with the shell deposition [177, 178]. For the 
post-shell formation protocol, the RNAs loading capacity is highly dependent on the 
porosity of the core inorganic materials. Based on the equation proposed by Sang et al. 
to describe absorption isotherm of biomolecules at their isoelectric point on nanoporous 
materials [179], using Equation (1):
(1)Γinternal = (NporeMNAδ )(VtAp)
where, Γinternal indicates the totally absorbed materials in the pores per mass of porous 
NPs, M is the molar mass of the biomolecules, NA stands for Avogadro’s number, δ 
stands for the dimension of the biomolecules, Vt is the total pore volume, Ap is average 
cross-sectional pore area, and Npore stands for the theoretical number of biomolecules 
that can reside in a single pore, which is correlated with the dimension of the 
biomolecules and pores. 
Considering the typical hydrodynamic dimension of siRNA with 20 base pairs is 6 nm 
× 3 nm [180, 181], the degree of cationic groups functionalization may only exhibit 
low-to-no effect on increasing the siRNA loading capacity in mesoporous materials 
with the pore diameter lower than 3 nm. This hypothesis was confirmed by Steinbacher 
et al. [182], who demonstrated for mesoporous silica NPs with pore diameter of 4 nm, 
degree of surface functionalization by cationic diethylenetriamine (DETA) showed 
minimal effects on siRNA loading degree. As with the increasing amounts of amine 
functionalization (pristine silica NPs treated with 0.5%, 2.5%, 15% DETA), the 
maximum specific adsorption of siRNA only marginally increased from 14 μg 
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(siRNA)/mg (silica NPs) to 18 μg/mg. However, a sharp contrast was observed for 
mesoporous silica NPs with pore diameter of 8 nm and 15 nm, where a ~3-fold 
maximum siRNA adsorption was observed (13 μg/mg vs. 36 μg/mg) [182]. It should 
be noted that, large pore size will conversely result in a weaker siRNA interaction at 
higher siRNA loadings, as the dissociation constant, Kd, increased with increasing 
amounts of amine functionalization. As a result, in a typical amine-functionalized 
mesoporous silica NPs with pore diameter ranging from 4 nm to 15 nm, 2040% of 
loaded siRNAs will be immediately released once upon re-dispersing into aqueous 
solution [182]. Thus, one potential issue for post-shell formation method is the potently 
reduced encapsulation efficiency due to the burst release of RNAs during shell 
formation process.
Typical in-situ shell formation process is usually achieved by adapting calcium ions. 
Calcium ions chelate and condense RNAs through the Ca2+/P binding, and the Ca–RNA 
complexes can be reversely disintegrated by competitive Ca2+ chelating agent or acidic 
condition [183, 184]. Taking advantages of the RNAs capturing capability, an in-situ 
shell formation process was developed for sealing the porous silicon NPs. As a result 
of the fast silicon backbone degradation, a high local concentration orthosilicic acid 
will be generated at the pore site. Upon the addition of solutions containing high 
concentrations of Ca2+ and siRNA, the porous structure will be sealed by the in-situ 
formed Ca2SiO4 shell structure and siRNA will be simultaneously entrapped in the shell 
structure [177, 178]. Similarly, calcium can also anchor and mineralize lipid or polymer 
layer to stabilize the nanostructure or generate a responsive RNAs release manner [185-
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187]. Comparing to directly adapting shell materials for loading RNAs, the core/shell 
formation is featured with self-limiting growth behavior, therefore can feasibly control 
the physiochemical characters of the nanocomplex by altering the core structure, and 
inorganic NPs core supported shell structure may also promote the stability of 
nanocomplex.
5. Targeting strategies
Efficient and precise targeting capability of NPs are of particular importance for NPs 
based RNAi due to the ultrahigh sensitivity of RNAi. However, in the field of NPs-
based RNAi, targeting methods showed no major difference with other NPs based 
targeting modalities, and readers may refer to more specific reviews regarding to the 
NPs targeting [188, 189]. In this section, however, we will only discuss the tendency 
of the recent studies, and highlight their outcomes in detail.
We identified recent changes over time on the target of NPs based RNAi by 
investigating changes in keywords from the top 200 most relevant scientific papers that 
include “nano” and “RNA interfering” over the periods 20162018 and 20192021. 
We manually selected relevant words associated with organs, tissue, and cells to focus 
on the target of NPs based RNAi. Our results (Figure 12) suggest that cancer targeting 
remains the hottest topic for NPs based RNAi throughout the two investigated periods. 
However, while NPs based RNAi have been applied into broader diseases criteria, we 
observed an increasing tendency in research works focused on manipulating the 
immune responses or navigating the NPs interaction with immune cells, as reflected by 
48
an increase over time of the frequency of keywords, including “Immunity”, 
“Inflammation”, “Vaccine”, “Cytokine”, “Macrophages”, and “Lymphocytes”. Table 
2 lists typical studies that conducted RNAi for immune cells during the recent years. 
Immune responses are pervasively involved in multiple diseases and can even be main 
pathogenesis regulator [190, 191]. Massive immune cells infiltration and accumulation 
is usually a key feature for lesional tissue [192, 193], therefore the targeting efficiency 
for organ or cells, such as heart and brain, which are conventionally thought to be 
difficult for targeting, can also be potentially increased by manipulating the NPs 
interactions with immune cells, and thus, are also drawing more attention for 
investigation (Figure 12).
Figure 12. Visualization of the most frequent words related to the organ/tissue/cells 
from keywords of scientific papers using Scopus Search “Nano” + “RNA interference” 
over two time periods: 20162018 and 20192021.
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Table 2. Recent examples of navigating NPs through targeting to immune cells.




Microglia Radiation therapy facilitate macrophages recruitment + iRGD peptide 
modification for recognizing αvβ3 and αvβ5 integrins
[194]
Brain
Microglia Surface modification of mannose [195]
Macrophages Altering the size of NPs [196]
Macrophages Surface modification of S2P peptide for targeting stabilin-2 receptor [73]
Macrophages Surface modification of mannose [197]
Macrophages Surface modification of CD36 antibody [198]
Heart
Macrophages Passive targeting by chitosan based NPs [158]
Tumor associated 
macrophages
Passively uptake by tumor associated macrophages [199]
M2 macrophages Surface modification of mannose [200]
Solid tumor
Circulating monocytes Changing the surface zeta potential from neutral to cationic [201]
Spleen and 
lymph nodes
CD4/8+ T cells Surface modification of anti-integrin β7 monoclonal antibodies [202] 






Neutrophils Decreasing the PEG percentage on NPs surface and enhance the surface 
zeta-potential
[204]
Macrophages Surface modification of fluorinated helical polypeptides [205]
Macrophages Surface modification of cyclic peptide CRV (sequence CRVLRSGSC) [206]
T cells Surface modification of cell-penetrating peptide dNP2 [207]
Lung
Macrophages Altering sizes of NPs [208]




niche to affect leukocytes 
behavior
Altering molecular weight and surface density of the PEG, altering the 
length of the lipid chain that anchors PEG, as a result, the formulation 
with lipid tail length C18, PEG Mw 5000 and PEG percentage of 10 






In situ light irradiation to switch the surface charge of NPs from 
negative to positive
[211]
For example, Bejerano et al. [196] developed a system able to target the macrophages 
recruited to the heart after myocardial infraction (MI) by taking advantage of the leaky 
vasculature and their accumulation in the site of inflammation. It is known that in the 
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infarcted myocardium the vasculature is leakier and allows the accumulation of 
particles with size comprised between 20 and 200 nm [212, 213]. Based on that, the 
authors developed a siRNA loaded NPs composed by hyaluronan-sulfate, Ca2+ and 
miRNA. The spontaneously formed nanocomplex obtain the size of 130 nm with 
surface zeta-potential of 10 mV. The cardiac targeting capability of the NPs was 
evaluated on mice with MI, which is established by left anterior descending (LAD) 
coronary artery ligation. NPs were injected intravenously and the heart of mice was 
collected five hour post NPs injection, and the authors found the highest cardiac 
accumulation was observed at 3 days post MI. Comparing to health mice, the cardiac 
NPs accumulation in MI mice was increased for over 25% [196]. Similar work was 
recently conducted by Tao et al., who specifically targeted lesional macrophages to 
improve atherosclerotic plaque stability [73]. siRNAs targeting Ca2+/calmodulin-
dependent protein kinase (CaMKIIγ) was loaded in cationic lipid–like material G0-C14, 
and the siRNA complex was further encapsulated by PLGA to better protect the siRNA 
core. Furthermore, a peptide called S2P, which recognizes the macrophage receptor 
stabilin-2, was conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamineN-
[maleimide(polyethylene glycol)] (DSPE-PEG-Mal), and the yielded DSPE-PEG-S2P 
was applied for coating the siRNA encapsulated PLGA NPs. Murine atherosclerosis 
model was established by feeding low density lipoprotein receptor deficient (Ldlr-/-) 
mice with adjusted calories diet (21.2% fat) for 12 weeks, followed with intravenous 
injection of NPs. In vivo results showed the specific macrophages targeting by S2P 
significantly increased the percentages of NPs containing macrophages in aortas 
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harvested from atherosclerotic mice 24 h after injection comparing to the non-targeted 
ones (14.4% vs. 5.7%), which resulted in lower plaque necrosis and increased lesional 
efferocytosis.
The immune cells targeting strategies are also adopted for targeting lungs. Kim et al. 
modified the siRNA containing fusogenic liposomes with a nine-amino peptide named 
CRV (sequence CRVLRSGSC) for targeting macrophages and further applied for 
Staphylococcus aureus lung infections [206]. CRV was selected in a phage library 
screen for cultured J774A.1 murine macrophages with selective macrophages targeting 
capability, and the CRV modification of fusogenic liposomes increased the lung 
accumulation of fusogenic liposomes to over 20% after 1 h of injection, which is mainly 
due to the specific NPs accumulation in macrophages after pulmonary Staphylococcus 
aureus infection (Figure 13A).
Besides of the direct targeting towards immune cells, other works by taking advantages 
of immune cells as RNAi vectors are also investigated. Wayne et al. cultured 
macrophages (C57BL/6 murine macrophages IC21) with siRNA loaded a 
commercially available lipoplex transfection reagent (geneSilencer, Genlantis) in vitro, 
and the adoptively transferred macrophages were further injected to mice for targeting 
breast cancer (xenograft model with MDA-MB-468 breast cancer cells) [214]. After 
injection, the macrophages infiltrated into solid tumor, with 2% of the total tumor cells 
were siRNA+. And the siRNA can be further excreted to the tumor microenvironments 
through Rab27a recycling pathway, sequentially exerting the gene knockdown function 
to cancer cells (Figure 13B).
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Figure 13. (A) Confocal microscope images of fluorescein (DiI) loaded fusogenic (F-
DiI-CRV) and non-fusogenic nanoparticles (NF-DiI-CRV) homed to infected lung with 
macrophages targeting moiety CRV. Different NPs are injected intravenously under 
healthy (1) or Staphylococcus aureus infection (2-4) conditions. Green, macrophages; 
red, DiI from NPs. (B) Schematic of horizontal RNA transfer facilitated by 
macrophages and corresponding exosomal secretory pathway. Modified and 
reproduced with permissions from (A) ref. [206]  Copyright 2018, Springer Nature; 
and (B) ref. [214]; Copyright  2019, Wiley-VCH.
From a technical point of view, for the targeting methods, the most commonly applied 
method is through the “targeting ligands functionalization” approach. However, 
chemical conjugation of targeting ligands may involve extra chemical reactions, which 
may be limited by complex procedures and high batch-to-batch variation. A recently 
developed biosynthetic method allow a customized routine to physically coat all types 
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of antibodies on the surface of NPs [78], which are further applied for targeting different 
leukocytes. A specific lipoprotein (anchored secondary scFv enabling targeting, 
ASSET) was biosynthesized and purified from Escherichia coli [215]. Composed by 
two critical segment: (1) N-terminal signal sequence followed by a peptide which will 
undertake lipidation in the membrane of Escherichia coli; and (2) single chain antibody 
fragment (ScFv) of a monoclonal antibody (clone RG7/1.30) to bind with crystallizable 
fragment (Fc) constant region of Rat IgG antibodies. This lipoprotein can effectively 
bind with a different types of antibodies with the dissociation constant Kd of ~22.7 nM, 
and the lipidized part can spontaneously inserted into LNPs which encapsulate siRNA. 
The ASSET-loaded LNPs can be coated with diverse antibodies to target different 
leukocytes including CD25+ T regulatory cells, CD3/4+ T cells, CD9+ B cells and 
CD11b+ monocytes in vivo.
Besides of the conventional “targeting ligands functionalization” approach, other 
efforts have also been made to achieve a targeting-ligands free manner for RNAs 
delivery towards specific leukocytes subsets. Among which, typical methods like 
tailoring the NPs’ surface property to alter the organ or cellular accumulation has been 
extensively investigated. The fundamental mechanism for the cell tropism from 
different NPs is speculated to be influenced by changes in their surface potentials and/or 
internal charges [216]. Generally, NPs with neutral surface charges exhibited longest 
circulation behavior, whereas anionic NPs (surface zeta-potential < 20 mV) strongly 
interact with reticuloendothelial system (RES), such as scavenging endothelial cells or 
blood resident macrophages, and cationic NPs are preferably uptake by virtually all cell 
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types, and they can be rapidly interact with the anionic surface of the blood vessel walls, 
and sequentially cleared via RES [217, 218]. Therefore, based on specific 
haemodynamics and resident cell type in different organs, the control over the internal 
and external charge of the NPs may subsequently resulted in organ or cellular tropism 
[219]. For example, Cheng et al. generated a strategy named as Selective Organ 
Targeting (SORT) which enabled the LNPs targeting of lung, liver and spleen [220]. 
Despite the paper aimed to deliver mRNA, Cas9 mRNA/ single guide RNA (sgRNA) 
and Cas9 ribonucleoprotein (RNP) complexes but not for RNAi, yet the detailed 
targeting strategy may be also transferred for RNAi based NPs design. In this work, 
different cationic, anionic, and zwitterionic molecules were added in different molar 
ratios to LNPs of pre-determined composition. The results found that with the 
increasing ratio of permanent cationic lipid SORT molecules (e.g., 1,2-dioleoyl-3-
trimethylammonium-propane, DOTAP; dimethyldioctadecylammonium, DDAB; 1,2-
dimyristoyl-sn-glycero-3-ethylphosphocholine, EPC) in the formulation, the major 
LNPs accumulation gradually transferred from the liver to the spleen and eventually to 
the lung. With the addition of 50% of DOTAP, 80% of the LNPs accumulated in lung 
and transfected ~40% of all epithelial cells, ~65% of all endothelial cells and ~20% of 
immune cells. Whereas the addition of anionic lipid SORT molecules (1,2-dioleoyl-sn-
glycero-3-phosphate, 18PA) enhanced the LNPs’ accumulation in spleen, which 
transfected ~12% of all B cells, ~10% of all T cells, and ~20% of all macrophages. 
Interestingly, addition of ionizable cationic lipid (1,2-dioleoyl-3-dimethylammonium-
propane, DODAP) significantly avoid the interaction with phagocytes, as rather than 
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Kupffer, 93% hepatocytes were transfected by the injected LNPs. Similarly, other 
reports suggested by reducing the surface PEG density and enhancing the surface 
charge could promote the NPs interaction with circulating monocytes and neutrophils, 
as such enhancing the siRNA delivery efficiency (Figure 14A,B) [201, 204]. The 
results suggested the critical function in manipulating the external/internal charges for 
altering the NPs interaction with immune cells.
However, this phenomenological approach to understand the “structure-tropism” is 
usually achieved with 1-by-1 in vivo analysis, which needs extensive lab work and 
animal numbers. A high throughput approach method is recently developed for 
screening T cells targeting NPs [203]. In this work, the authors adapted a phage-library-
like strategy, and formulated over 100 types of LNPs with different lipid composition. 
Each type of LNPs will co-encapsulate a unique type of DNA sequence, as the function 
of “barcode” to identify the LNPs, and siRNA to knockdown GFP as RNAi readout. 
Then different LNPs were mixed, and the “LNPs cocktail” was injected to GFP 
expressing mice. After 3 days, the GFPlow cells were isolated and the “barcode DNAs” 
were deep sequenced for determining the LNPs that are preferably colocalized in 
GFPlow cells (Figure 14C). In this manner, the authors screened out an ionizable lipids 
which endows the LNPs massive accumulation in splenic T cells, and concluded that 
helper lipid DSPC containing LNPs will facilitate the splenic T cells targeting whereas 
DOPE containing LNPs will conversely reduce the ability. 
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Figure 14. (A) Increasing the neutrophil targeting capability of NPs can be achieved 
by increasing the percentage of cationic lipid (N,N-bis(2-hydroxyethyl)eN-methyl-N-
(2-cholesteryoxycarbonyl-aminoethyl) ammonium bromide, BHEM-Chol), or reducing 
the PEG density on NPs’ surface. As a result, the formulation with the term CLAN45 
exhibits best neutrophils interaction capability. (B) Increasing the surface charge can 
also promote the targeting capability of siRNA loaded NPs towards monocytes. (C) 
Scheme for high throughput screen to select ionizable lipids which can potentially 
enhance the targeting capability of LNPs towards T cells. Modified and reproduced 
with permissions from (A) ref. [204]; Copyright  2018, Elsevier B.V.; (B) ref. [201]; 




Endosome escape is the last, but a critical step, for successful NPs based RNAi [19, 
20]. During the past decades, there has been significant progress in endocytosis 
mechanism and endosomal environment research. Such knowledge provides the basis 
of endosomal escape strategies, and the related endosomal escape mechanism studies. 
In the following sections, we first introduce the endosomal environment. Then we 
explain the current understanding of different endosomal escape mechanisms, and 
introduce the common reagents and materials used for siRNA endosomal escape. 
Specifically, we highlight prototypical examples of siRNA endosomal escape systems, 
and analyze the advantages/disadvantages of the material designs. Finally, we discuss 
the critical challenges and unresolved issues in the endosomal escape progress for 
future development.
6.1. Physiological environment for different endosome compartment
As we discussed in Section 2.2., endosome escape of siRNA will exclusively occur in 
specific endosome compartment. Therefore, understanding the physiological properties 
for each compartment is important for guiding the design and choose of endosome 
escape materials. Despite the different uptake mechanisms, most uptake vesicles fuse 
with early endosomes (EE). EE plays a very important role in the endocytosis process, 
because it acts as a “sorting center” of the endocytosed substances [39], similar to the 
sorting center of parcels in real life. The housekeeping membrane proteins, such as 
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transferrin receptors, are recycled to the plasma membrane surface, while those proteins 
to be downregulated go through the endosomal maturation process and degraded in 
lysosomes eventually. The different fate of endocytozed vesicles are regulated mainly 
by the Rab family of GTPases [221]. There are 70 Rab encoded in human’s genome 
and more than 40 Rab are involved in the endocytic pathway regulations [222]. For 
example, Rab5 is enriched on EE membranes, and subsequently switch to Rab9 on late 
endosomes (LE, also named as multivescular body, MVB) membranes [221]. These 
Rab GTPases on the endosomal surface are similar to the barcode stick to the parcels, 
which direct the endosomal vesicles to different destinies. The directed transport relies 
on the binding of endosomal vesicles to actin filament- and microtubule-associated 
motors [221]. For example, Rab11 is a critical protein on the recycling endosomal 
surface [223]. By binding with actin filament-motor MYO5B, Rab11coated endosomes 
are exclusively transported back to plasma membranes [224]. Such delicate regulation 
of endosomal vesicles in the intracellular trafficking suggests the critical role of 
endocytosis for cell metabolism. Thus, the potential damage to the endocytosis 
machinery may lead to the metabolic disorder within the cell, or even cell death.
Regarding the endosomal environment, the membrane-bounded endocytic vesicles are 
very dynamic, with continuous ions and substances exchange with cytoplasm, Golgi 
apparatus and endoplasmic reticulum (ER) [39]. Specifically, endosomal environments 
have several characteristics distinguishable from cytoplasmic and extracellular 
environments. The most prominent character is the acidic lumens. The pH continuously 
decreases from early endosomes (pH 6.16.8) to late endosomes (pH 4.86.0), and 
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finally to lysosomes (pH around 4.5) [39]. The unique acidity is because of the 
continuous proton influx by vacuolar H(+)-ATPases (V-ATPases) [225]. The 
acidification of endosomal lumens is crucial for endosomal function, because it allows 
for the uncoupling of receptors and the binding ligands, and for maintaining the 
enzymatic activities within lysosomes. The acidic endosomal lumens also inactivates 
toxins and pathogens uptake by endocytosis, and protects cells from foreign invasions. 
Other acidity, endosomal lumens also have identical ion concentrations compared with 
extracellular fluids. For example, Na+ concentration decreases along the endosomal 
pathways from 120 mM (in extracellular fluids) to 20 mM (in lysosomes), while K+ 
concentration gradually increases from approximately 5 mM to 60 mM [226]. Like Na+, 
Ca2+ concentration has been found much lower in endosomal vesicles [227]. Regarding 
anions such as Cl-, the concentration in EE is lower than extracellular environment, but 
during endosomes maturation, Cl- concentration showed an increased trend probably 
due to the ion exchanges through intracellular chloride channels [228]. Similar to pH 
homeostasis, ion balance is important for endosomal function, including luminal 
osmolality maintenance, pH regulation, protein activation or even endosomal 
membrane curvature [226]. 
Besides the luminal contents, endosomal membranes have attracted significant 
attention because of their characteristic lipid compositions [229]. Although EE shares 
the similar membrane composition as plasma membranes, LE has a unique lipid, 
lysobisphosphatidic acid (LBPA) (or bis(monoacyl glycero)phosphate, BMP) [230]. 
Despite the continuous membrane flow and vesicle fissions/fusions, LBPA is 
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exclusively presented on EE membranes, and the membranes of intraluminal vesicles 
inside EE [229]. 
Based on the unique characters of endosomal lumens and membranes, there are several 
strategies developed for the endosomal escape, by entire endosomal rupture, or 
endosomal membrane destabilization or membrane fusion [231]. It is critical to ensure 
that all these strategies use endosomal environmental components, such as protons, 
enzymes and lipids, as triggers to ensure that the membrane disruption is limited to 
endosomes and lysosomes. Otherwise, the universal disruption on cellular membranes 
will lead to undesirable toxicity. In the following sessions, we will explain these 
endosomal escape strategies and discuss specific delivery systems applying these 
strategies.
6.2. Endosomal escape by rupture
Endosomal rupture is the first and most prominent endosomal escape strategy proposed 
[232]. Different types of endosomal rupture mechanisms are summarized in Figure 15. 
Endosomal rupture can originate from imbalanced osmotic pressure between the 
endosomal lumen and cytoplasm (Figure 15A). As V-ATPases import protons to 
endosomes, the counter ions Cl- are also imported to balance the charge [233]. The 
chloride ion influx is accompanied by water influx, which increases the osmotic 
pressure inside endosomes [234]. In the presence of a buffering polymer, excessive 
protons are supposed to flow inside the endosomes, because the buffering polymer 
inhibit the endosomal acidification. The excessive protons, Cl- and water intensify the 
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endosomal swelling and eventually lead to endosomal rupture [235]. 
This so-called “proton-sponge” hypothesis has been proposed to explain the endosomal 
escape mechanism of several cationic macromolecules, such as PEI, PDMAEMA, 
chitosan and PAMAM [232]. These polymers have ionizable primary, secondary, 
tertiary amine groups with buffering capacities within endo/lysosomal pH ranges [235]. 
However, evidence has shown that the buffering capacity alone does not make polymers 
escape from endosomes [236]. It was found that on model lipid membranes and plasma 
membranes, cationic PEI and PAMAM interact anionic membrane lipids via 
electrostatic interactions, and destabilize local membranes to create nanoscale pores 
[237]. This is supported by the real-time confocal microscopy images, confirming that 
PEI polyplexes induced transient membrane pores, where the payloads were burst 
released to the cytoplasm [238]. These results indicate that the “proton sponge” effects 
did not cause complete endosome lysis. Instead, after endosomal swelling, cargos 
escape from endosomes by the membrane defects caused by cationic polymer carriers 
(Figure 15A).
However, recent evidence argues the role of membrane defects during endosomal 
escape. Vermeulen et al. found that the membrane defects may prevent endosomal 
escape of macromolecular cargos [239]. In their study, similar burst release of 
oligonucleotides from endosomes enabled by PEI carriers was observed, but the release 
only happened to <10% polyplexes containing endosomes. Despite the unsuccessful 
escape, the majority of endosomes showed membrane leakiness, evidenced by the 
release of a small fluorescent molecule. The authors hypothesized that the membrane 
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leakiness prevented effective buildup of the osmotic pressure, thus preventing the 
cargos from burst release. The authors also found that endosomes with smaller sizes 
were more prone to the burst release than those larger ones, indicating both the size and 
membrane leakiness played a role in the final endosomal escape.
While the exact mechanism of “proton sponge” is still under debate, other approaches 
to induce endosomal rupture are being investigated. For example, vapor nanobubbles 
are proposed to break the endosomal vesicles, triggered by ultrasound or laser (Figure 
15B). The bubble liposomes filled with perfluoropropane gas were applied to cells pre-
treated with pDNA encapsulated liposomes [240, 241]. Then the cells were exposed to 
ultrasound, inducing transient pores for endosomal escape [242]. In terms of laser-
triggered nanobubble generation, plasmonic nanoparticles (typically gold NPs) are 
applied to cells, exposed to high energy pulsed laser. The energy of the laser pulse (<10 
ns) is transferred to heat by the gold NPs and vaporizes the surrounding water, 
generating nanobubbles, which quickly expand from the gold NP’s surface and collapse 
[243]. The mechanical energy of the shock wave can generate transient pores on 
endosomal vesicles, allowing for endosomal escape of protein, siRNA and pDNA [244]. 
It was found that the endosomal escape enabled by laser-induced nanobubbles is 
efficient, and independent of cell type [245]. Moreover, with optimized laser energy 
and exposure time, this technique was non-cytotoxic, without any long-lasting effects 
on cell hemostasis [245]. 
Finally, some carriers can induce endosomal membrane rupture simply by physically 
piercing the membrane. For example, some NPs have sharp or prickly surfaces, which 
63
enables much better cytoplasmic delivery than the round counterparts. This has been 
evidenced by prickly nanodiamonds, zinc-doped copper oxide nanoparticles, and star-
shaped gold NPs [246, 247]. Another example reported a liquid metal NP, which has 
light-induced morphology transformation from nanospheres to nanorods [248]. The 
high aspect ratio nanorods led to physical disruption of endosomal membranes, 
visualized by confocal and electron microscopies [248]. Despite the endosomal escape 
capability, prickly nanocarriers should be used with caution, due to the potential 
damage to plasma membranes and the toxicity related to endosome impairment.
Figure 15. Schematic showing of different mechanisms of endosomal rupture. (A) 
“Proton sponge” hypothesis mediated by cationic buffering polymers. Endosomal 
rupture is induced by osmotic pressure between the endosomal lumen and the 
cytoplasm. (B) Nanobubble strategy induced by laser or ultrasound triggers. Endosomal 
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rupture is induced by the mechanical force when nanobubbles expand and collapse. (C) 
Physical disruption of endosomal membranes by prickly carriers. Endosomal rupture is 
induced by the mechanical force from the sharp surface piercing membranes. Created 
with BioRender.com.
6.3. Endosomal escape by membrane destabilization and membrane fusion
Endosomal escape by membrane destabilization and membrane fusion represents 
another strategy widely used, especially by virus and bacteria [249]. As indicated in the 
nomination, membrane destabilization carriers interact with endosomal membranes 
directly, and cause membrane defects or even pores to allow for the escape (Figure 
16A). Membrane fusion inducer may penetrate inside the endosomal membrane and 
induce fusion to release the cargo (Figure 16B). Therefore, the tendency of carriers to 
associate with endosomal membranes and the capability to disrupt the lipid bilayers are 
crucial factors for successful endosomal escape. In the following paragraphs, we 
introduce three typical carriers for membrane destabilization and fusion, including cell 
penetrating peptides, amphiphilic endosomolytic polymers and fusogenic lipids, and 
discuss how the structure, charge and amphiphilicity affect the membrane 
destabilization and the escape.
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Figure 16. Schematic showing of different mechanisms of endosomal membrane 
destabilization by (A) endosomolytic molecules (CPPs, small molecules or polymers) 
and (B) fusion with lipid-based delivery systems. Created with BioRender.com.
6.3.1. Cell penetrating peptides (CPPs)
Although some CPPs translocate through cell membranes to deliver cargos directly to 
cytoplasm, the endocytic uptake and the following endosomal escape is still the major 
internalization route for CPP-cargo complexes [250]. Considering the great diversity in 
CPP structure, physiochemical properties of CPP-cargo complexes, and endocytosis 
pathways, the membrane destabilization mechanisms vary [250]. For example, 
amphiphilic CPPs, such as hemagglutinin-2 (HA2), INF7 (the N-terminal domain of 
HA2) and GALA (a synthetic peptide with a glutamic acid-alanine-leucine-alanine 
repeat), have pH-responsive conformational changes [251, 252]. At acidic endosomal 
pH, the protonation of glutamic acid (Glu) transformed the CPPs into α-helix structure, 
which enables the CPPs to penetrate into the endosomal membranes, and induce pore 
formation (Figure 16A) [253]. Arginine-rich CPPs (such as TAT, penetratin, 
oligoarginine), however, induce membrane-destabilization by electrostatic interaction 
66
and hydrogen bonding with negatively charged membrane lipids and polysaccharides 
from membrane proteoglycans [254]. Recent studies found that the guanidinium groups 
from arginine residues have strong affinity towards negatively charged lipids in the LE, 
especially BMP [255]. The association with BMP led to membrane fusion between the 
intraluminal vesicles in the LE, and with LE outer membranes to allow the cargo escape 
(Figure 17) [256]. 
Figure 17. Schematic showing of BMP-dependent endosomal escape from LE. The 
guanidinium groups from arginine residues interact with BMP head groups. The 
interaction results in membrane fusion and leakage. Inside late endosomes, the arginine-
rich CPP (a dimerized TAT, denoted as dfTAT) and the macromolecular cargos 
translocate into the cytosol by leaky fusion events (two non-mutually exclusive 
scenarios involving intraluminal vesicles and the limiting membrane of the organelle 
are represented). The introduction of anti-BMP monoclonal antibody blocks the fusion 
and subsequent leakage, confirming the endosomal escape mechanism. Modified and 
reproduced with the permission from ref. [256]; Copyright  2016, Elsevier B.V. 
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Along with increased understanding of CPP endosomal escape mechanisms, significant 
efforts have been made to balance the endosomal escape capability and cytotoxicity, by 
modification of the natural CPP structure [257]. Although arginine-rich CPPs like TAT 
and oligoarginine are the prototypical examples for intracellular delivery applications, 
the naïve form of these CPPs are mostly trapped in endosomes [258]. Therefore, many 
studies dedicated to find out how to increase the endosomal escape property by 
changing characteristic parameters of a peptide, such as amino acid sequence, length 
and the topological structure [257, 258]. To this end, Pellois’ lab has systemically 
investigated TAT variants with different guanidinium density, branching structure and 
chirality. They found a typical threshold of at least 10 arginine is essential for 
endosomal escape [259]. This is consistent with other reports with oligoarginine 
peptides with different lengths [260]. Dimerization or trimerization of TAT 
significantly improved the endosomal escape efficiency, despite the increased 
cytotoxicity of TAT multimers [261]. The multivalent effects derived from branching 
structure increase the membrane interaction, thus facilitating the escape but also 
increased the toxicity unfortunately [260]. Furthermore, the endosomal escape 
efficiency is affected by the chirality of the CPPs. Although cells have preferable uptake 
of natural L-amino acid peptides, peptides synthesized by artificial D-amino acids have 
longer half-lives because of the slower degradation by proteolytic enzymes [262]. The 
longer half-life is however, multifaceted. On one hand, it is beneficial for endosomal 
escape because of the long-lasting endosomolytic activity [263]. One the other hand, it 
is also associated with pronounced cytotoxicity because of the prevalent membrane-
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lytic effects to organelles in the cytoplasm [263]. Other than changing the parameters 
from peptide synthesis, chemical ligation on natural CPP structure is another approach 
to enhance the endosomolytic activity. The conjugation of hydrophobic moieties (e.g., 
stearyl, phenyl, and aromatic indole rings) promotes the endosomal escape [252, 264]. 
Both experimental data on model lipid membranes and computational simulations 
prove that hydrophobic groups facilitate the insertion inside the lipid bilayers, which 
contributes to the membrane association and the potential to create membrane leakiness 
[265]. 
Another approach to find optimal CPPs for endosomal escape, is to convert highly 
membrane-lytic cationic amphiphilic peptides into pH-dependent variants [266]. 
Instead of enhancing the membrane destabilization activity from those weak endosomal 
escape peptides, this approach selects the strong membrane-lytic candidates derived 
from venoms or antimicrobial peptides, and attenuates the their membrane-lytic activity 
at physiological pH by introducing anionic Glu residues or aspartic acid (Asp) residues 
[267]. The negative charge from both Glu and Asp decreases the interaction of these 
peptides with cell membranes, and thus, decreases the cytotoxicity. At endosomal pH, 
the protonation of Glu and Asp helps to recover the membrane-lytic activity to realize 
the endosomal escape. This strategy mimics the amphiphilic viral peptides HA2, which 
only initiates the endosomolytic activity upon acidification [253]. With Glu or Asp 
substitution, toxic and hemolytic peptides, such as M-lycotoxin, melittin, δ ‐
hemolysin, chrysophsin and ponericin-W3, could be converted to attenuated variants 
with endosomolytic activity [267, 268]. The replacement position of Glu is critical to 
69
manipulate the variant’s cytotoxicity and endosomolytic activity [268]. It is optimal to 
substitute Glu on the boarder of the hydrophobic and hydrophilic face within the α-
helical structure, because the substitution on the hydrophobic face diminished the 
membrane interaction capability completely, while the substitution on the hydrophilic 
face had little effects on the cytotoxicity [268]. 
Alternatively, the toxic CPPs could be masked by acid-cleavable protective groups and 
pH-responsive micelles [269]. By reacting with dimethylmaleic anhydride, the amine 
groups on cationic lysine and arginine residues could be converted into carboxylic acid 
groups with negative charges at physiological pH [269]. The charge conversion 
significantly reduced the cytotoxicity and hemolytic activity of melittin, and the 
membrane-lytic activity was restored after acid-induced cleavage of masking groups 
[270].
6.3.2. Endosomolytic polymers
Endosomolytic polymers have been developed mimicking the structure of CPPs. 
Inspired by arginine-rich CPPs, guanidinium-containing polymers with different 
backbones, molecular weights and topological structures have been synthesized for 
intracellular delivery [271-274]. Noticeably, the polymer backbone played an important 
role in membrane destabilization. For example, guanidinium-containing 
poly(disulfide)s have unique disulfide exchange with proteins on the plasma membrane, 
thus facilitating the association and translocation capacity of the polymers [275]. 
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Regarding the topological structure, branching and dendritic structures generally have 
higher potency in endosomal escape [272], despite sometimes associated with higher 
cytotoxicity [271]. Regarding molecular weights, guanidinium-containing 
homopolymers and their analogues with longer chains (degree of polymerization, DP = 
89) displayed higher siRNA transfection efficiency than shorter analogues (DP = 8, 22 
and 43) at the same mass concentration (Figure 18) [276]. This was attributed to the 
charge distribution within the molecule by the authors [276]. Polymers with higher 
molecular weights displayed a densely charged coil, focusing on the membrane to 
induce destabilization. Although the higher transfection efficiency was also observed 
on other long chain polymers with different compositions [277], this charge-density 
membrane-destabilization hypothesis needs further investigation and validation. 
Similarly, higher molecular weight polymers are associated with higher cytotoxicity 
(Figure 18), possibly due to the non-biodegradability and accumulation in cells [278]. 
Thus, biodegradable monomers or linkers could be applied to achieve high molecular 
weight with lower cytotoxicity [279].
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Figure 18. The molecular effects on guanidinium-containing homopolymers and their 
analogues. (A) The structures of polymers and (B) their transfection efficiency and 
cytotoxicity in HEK293T cells. Reproduced with the permission from ref. [276]; 
Copyright  2020, Royal Society of Chemistry.
In addition to guanidinium-containing polymers, pH-responsive fusogenic amphiphilic 
polymers are intensively explored, for endosomal escape purposes. The pH-induced 
protonation of Glu and Asp on fusogenic CPPs, is mimicked by various carboxylic acid 
containing amphiphilic polymers [280, 281]. It is noticed that the balance of 
hydrophobic and hydrophilic monomers is important for their function. For example, 
adding a small portion of hydrophobic units (i.e., 2% cholesteryl methacrylate or 10% 
lauryl methacrylate) on poly(methacrylic acid) significantly increased its membrane 
association capability [280]. However, excessive hydrophobic units (i.e., 8% 
cholesteryl methacrylate or 40% lauryl methacrylate) compromised the polymer 
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solubility and decreased the membrane interaction, because of the enhanced association 
between polymer chains [280].
The mechanisms of most endosomolytic polymers remain inconclusive, partially due 
to the abundant structural diversity and the general focus in the field. Most studies focus 
more on the delivery efficiency and the overall therapeutic efficacy rather than the 
detailed mechanism inside the cells. Another difficulty may come from the polymer 
synthesis. Despite the huge achievements in polymerization techniques, it is still 
difficult to achieve complete control over the polymer sequence, at least not on 
monomer level. Therefore, it is not possible to study the subtle change on a single 
polymer chain (e.g., the addition or substitution of one or two residues). Unlike the 
small molecules or peptides synthesized with identical structure, synthetic polymers 
may have monomers distributed statistically along the chain. Thus, their membrane 
destabilization behavior should be interpreted as the average potency from the whole 
polymer population with the same monomer composition.
6.4. Lipids
In Section 4.1, we discuss the general methodology and mechanism of efficient RNAs 
encapsulation by LNPs, whereas in this section, we will mainly focus on the other 
critical aspect of LNPs design: commonly used method and the potential mechanism 
for enhancing endosome escape capability of LNPs. Of course, lipid NPs may directly 
fuse with plasma membrane and translocate payloads into cytoplasm without 
endocytosis. However, endosomal escape remains to be the main internalization route 
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for lipid-based gene delivery systems [238]. The functional lipids for endosomal escape 
could be categorized according to their physiochemical properties: cationic lipids (e.g., 
DOTAP), neutral phase transition inducer lipids (so-called “helper lipids”, e.g., DOPE) 
and pH-dependent conformation switchable lipids [104]. Because LNPs and liposomes 
are usually formulated as a mixture of different lipids, the lipids for endosomal escape 
purposes usually only constitute a small portion, with the majority composed of PC, 
cholesterol, PEGylated lipids, etc., to stabilize the final NPs [102]. Therefore, the final 
endosomal escape properties resulted from combinational effects of the whole lipid 
formulation, instead of single membrane-destabilization moieties. 
The endosomal escape mechanism of LNP and liposome are generally attributed to the 
fusion with endosomal membranes (Figure 16B). As endosomal membranes are rich 
in anionic lipids, the cationic lipids enhance the membrane interaction by electrostatic 
interactions [97, 282]. Once located on the endosomal membrane, the fusogenic lipids 
(DOPE) transformed the lipid phase from lamellar to inverted hexagonal, thus 
promoting the membrane fusion [283]. This theoretical explanation is as popular as the 
“proton-sponge effect”, and has long been accepted in the field [282]. However, recent 
evidence suggest the translocation could happen by a transient pore model rather than 
fusion [238]. The authors found the endosome release of oligonucleotides by LNPs was 
in a gradual manner, which fits better to the “pore forming” mechanism, where a more 
subtle endosomal membrane destabilization, rather than a burst membrane fusion, can 
achieve (Figure 19A-C) [238]. In this new hypothesis, after interaction with endosomal 
membranes, the lipids from endosomal membranes could be taken away by LNPs, thus 
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creating transient pores for payload to escape, which is similar to membrane 
destabilization created by CPPs and endosomolytic polymers discussed in the previous 
sections (Figure 19D) [284]. This is evidenced by the endosomal damage markers and 
small cytosolic Ca2+ transients [20]. Despite the emerging evidence, more studies are 
needed to elucidate this new hypothesis.
Figure 19. (A) HeLa cells incubated with Lipofectamine2000 carrying FITC-ODNs 
and monitored by confocal microscopy. White arrows indicated two NPs successively 
released parts of the ODN content, revealing a stepwise decrease in ODN fluorescence 
within the endosome, and a concomitant increase in ODN fluorescence within the 
nucleus. (B) Rhodamine-labeled Lipofectamine2000 (red) was complexed with FITC-
ODNs (green) and added to HeLa cells. Three lipoplex-containing endosomes that 
initially appear yellow (due to colocalization of carrier (red) and contents (green)) 
gradually turn red while releasing ODNs into the cytoplasm. (C) The fluorescence of 
the particles (labelled with white arrows) and the nucleus showing in (A). (D) The 
schematic showing of the transient “pore-forming” mechanism induced by lipid-based 
delivery system. Modified and reproduced with the permission from (A-C) ref. [238]; 
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Copyright  2013 American Chemical Society; and (D) ref. [284]; Copyright  2019 
American Chemical Society.
Despite the successful delivery mediated by cationic lipids, the associated toxicity and 
immunogenicity was still a concern [285]. To solve this problem, pH-sensitive lipids 
have been developed. Typically, these lipids have ionizable head groups, which are 
protonated only in acidic endosomes [53]. Through high-throughput screening, several 
ionizable lipid candidates have been identified [99, 286], and the related formulations 
showed pKa, phase transition temperature, number of hydrophobic tails and the tail 
saturation state are key factors in the design [287, 288]. A pKa within EE pH range, 
lower transition temperature and unsaturated branched tails are beneficial to enhance 
endosomal escape properties [287, 288]. Furthermore, the conformational change of the 
ionizable lipid at molecular level with head-tail orientation switch could also facilitate 
the escape [289].
6.5. Small molecules facilitate endosome escape
A group of small molecules, termed as cationic amphiphilic drugs (CADs), have been 
shown to obtain the membrane-destabilizing properties [290, 291]. These drugs all had 
protonable secondary or tertiary amine groups. At physiological pH, these groups are 
not protonated, and the drugs can diffuse into the lysosomal lumen, where they are 
protonated upon acidification. The positive charge and the increased hydrophilicity 
prevents them from diffusing out of phagocytic compartments. Therefore, the drugs 
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retain in endosome/lysosomes, and inhibit lipid hydrolyzing enzymes especially acid 
sphingomyelinase [291]. Therefore, a hypothesis has been proposed to facilitate the 
RNA endosome escape due to the membrane disruption [290, 292]. Recent studies tried 
to develop endosomolytic molecules with better efficacy by repurposing FDA-
approved cationic amphiphilic drugs, such as carvedilol, desloratadine, nortriptyline 
and salmeterol, and when co-administrated with siRNA carriers, the drugs, acting as 
“endosomal escape adjuvants”, may enhance siRNA delivery efficiency both in vitro 
and in vivo [290, 292]. However, as we discussed in Section 2.2., release of the RNA 
payload may only has a particular “window of opportunity” during the endosomal 
maturation process, yet CADs are diverse and target multiple intracellular 
compartments. Therefore, it is important to understand whether the mismatch between 
NPs containing and CADs-targeted compartments will hinder the further knockdown 
efficiency improvement.
A recent study selected three different CADs (chloroquine, siramesine and 
amitriptyline), and separately investigated their corresponding effects on the gene 
knockdown efficiency from cholesterol-conjugated siRNA targeting d1-eGFP [293]. 
All these drugs can induce obvious endosome/lysosome rupture as reflected by 
galectin-3 and galectins-9 recruitment in the endosomal membrane, which is a typical 
signal for endosome damage (Figure 20A) [19, 20]. This membrane destabilization 
capability further improved siRNA-mediated knockdown in HeLa cells expressing a 
destabilized enhanced GFP (HeLa-d1-eGFP), yet the enhancement efficiency varied 
from drug to drug. Chloroquine lowered half-maximal inhibitory concentration (IC50) 
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for over 17-fold, whereas the number for amitriptyline and siramesine was only ∼2- 
and 4-fold, respectively (Figure 20B). The authors purposed the following explanations 
for this phenomenon. First, the authors compared to other drugs, chloroquine exhibited 
better capability in triggering cytosolic release of macromolecules. This was confirmed 
by applying 10 kDa fluorescent dextran as cytosolic release indicator (Figure 20C). 
Internalized dextran was solely located in intracellular vesicles, whereas after 
incubating HeLa-d1-eGFP cells for 16 h with different CADs, chloroquine treatment 
group triggered the most significant cytosolic dextran release, which was 8-fold higher 
than siramesine treatment group, and amitriptyline treatment only provoked low-to-no 
cytosolic redistribution of dextran. The observed results were in consistence with the 
as-mentioned knockdown enhancement efficiency, indicated the enhanced siRNA 
endosome escape is correlated with the membrane destabilization degree. 
Secondly, different drug targeted different phagocytic compartments. Authors 
identified the detailed compartments damage by different drugs, and divided the 
phagocytic compartments via the endosome maturation stages. For chloroquine treated 
HeLa-d1-eGFP cells, 43% of the damaged endosomes were featured as Rab5+ 
(immature early endosome), while Rab5 was not recruited to vesicles damaged by 
siramesine. On the contrary, siramesine mainly showed damage towards Rab9+ 
structures (late endosomes), as 42% of the Rab9+ compartments were shown as 
galectins-9+, whereas this number for chloroquine group was only 23%, suggesting 
chloroquine mainly interrupt the membrane integrity of endosome at early stages 
(Figure 20D). This is in good line with previous results, suggesting the siRNA 
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endosome escape majorly occurs in early endosome stages [19, 20]. Herein, the results 
further confirmed that, comparing to early endosomes, the disruption of late endosome 
or lysosome may show restrained effects on promoting the RNAi.
Besides of the CADs-specific effects on knockdown efficiency, the same CAD may 
exhibit altered effects on different delivery systems. For example, Wittrup et al. showed 
that treating HeLa-d1-eGFP (same cell line in Ref. [293] as discussed above) with 
chloroquine conversely reduced the knockdown efficiency of GFP targeting siRNA 
loaded in LNPs [20]. This difference can be attributed to the different endocytosis 
pathway from different delivery system. As phagocytosis of LNPs is mainly dominated 
through clathrin-dependent endocytosis [16], which can be effectively inhibited by 
chloroquine [294]. However, cellular uptake of cholesterol-conjugated siRNA is partly 
initiated with the cholesterol insertion into the cholesterol rich raft area of cell 
membranes, followed by internalization through caveolin-dependent endocytosis (also 
named as raft-dependent endocytosis) [295, 296]. Therefore chloroquine reduced 
siRNA knockdown efficiency from lipid NPs can be partly explained as the decreased 
intracellular NPs accumulation. Similar phenomenon was observed by Gilleron et al., 
who screened a CADs compound library for evaluating effects of different CADs on 
RNAi from siRNA loaded lipid NPs and cholesterol conjugated-siRNAs. Despite in 
total 51 CADs exhibited RNAi enhancing efficiency, most enhancers displayed 
specificity for one delivery system only [297], confirming the delivery system specific 
effects from CADs.
CADs induced endosome escape is also cell type dependent. For example, pretreating 
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HeLa-d1-eGFP cells with 20 μM loperamide could induce a 47-fold siRNA IC50 
reduction (Cholesterol-conjugated siRNA), whereas this RNAi enhancing efficiency 
was slightly observed in MCF-7-d1-eGFP breast cancer cells [293].
Overall, despite CADs induced RNAi enhancing has been observed, its further clinical 
application may be hindered by the multiple varieties and further investigations should 
be conducted to provide systematic guidance for proper CADs choose.
Figure 20. Enhanced RNAi efficiency from CADs. (A) HeLa cells incubated with 10 
μM siramesine, 50 μM of amitriptyline or 50 μM of chloroquine for 24 h, and the 
galetin-3 were stained for as endosome damage indicator. Scale bar indicates 50 μm. 
(B) HeLa-d1-eGFP cells were first incubated with cholesterol-conjugated siRNA for 6 
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h, sequentially treated with 10 μM of siramesine, 60 μM of amitriptyline or 60 μM of 
chloroquine for 18 h. Then evaluate the GFP knockdown by flow cytometry. The 
knockdown enhancement efficiency is qualitatively correlated with the galetin-3 foci 
number in (A). (C) Correlation between number of galectin-9 foci and median cytosolic 
dextran fluorescence intensity per cell after 16 h CADs treatment. Cell number for 
control, amitriptyline, siramesine and chloroquine are separately 953, 1204, 1177, and 
1139. Linear regression is outlined by red line. (D) Evaluated damaged vesicles 
numbers and their corresponding fraction within the total vesicles with endosomal 
markers. Modified and reproduced with permission from ref. [293]; Copyright  2020, 
Springer Nature.
7. Future perspective of non-viral NPs based RNAi
7.1. Clinical translation of non-viral NPs based RNAi
Last, but not the least, we discuss about the clinical translation of non-viral NPs based 
RNAi. By summarizing the clinical translation of RNAi-based NPs, one can better 
understand the practical obstacles and challenges during NPs design and fabrication. 
By considering the general advances and failures in the field of nucleic acid delivery 
and the different formulation strategies used in clinically approved products, we hope 
to provide insights, from a market point of view, for future designing and optimization 
of NPs’ formulations.
7.1.1 Approved nucleic acid therapies
The first nucleic acid therapy approved by FDA in 1998 was Vitravene (fomivirsen) by 
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Ionis Pharma and Novartis, a phosphorothioate antisense oligonucleotide for the 
treatment of cytomegalovirus renitis [298]. It was followed by Macugen (pegaptanib), 
a PEGylated aptamer for the treatment of neovascular age-related macular degeneration 
in 2004 [299], and nine years later by Kynamro (mipomersen) a gapmer oligonucleotide 
for treating homozygous familial hypercholesterolaemia [300]. These pioneering 
products faced commercial difficulties; Vitravene was withdrawn as a result of reduced 
clinical need [301] and the sales of both Macugen and Kynamro were limited due to 
competition [302, 303]. Furthermore, Kynamro’s safety concerns led to its rejection by 
the European Medicines Agency (EMA) [304]. 
The latter half of 2010s saw a renaissance of oligonucleotide based therapies as new 
wave of products reached the clinics. Among these was the first FDA-approved RNAi 
drug and the first approved nanomedicine for nucleic acid delivery, Onpattro, in August 
2018 [107]. Onpattro, developed by Alnylam Therapeutics, is a lipid complex injection 
of patisiran (siRNA) for the treatment of hereditary transthyretin-mediated amyloidosis. 
Of the recently approved oligonucleotide products, Onpattro (patisiran) is the only one 
that is based on nucleic acid encapsulated inside NPs. Spinraza (nusinersen), Tegsedi 
(inotersen), Exondys 51 (eteplirsen) and Vyondys 53 (golodirsen) are naked chemically 
modified ONs [305-307], Givlaari (givosiran) and Oxlumo (lumasiran) are N-
acetylgalactosamine (GalNac) conjugated siRNAs [308], Luxturna (voretigene 
neparvovec) and Zolgensma (onasemnogene abeparvovec) are DNAs delivered by 
adeno-associated viral vectors (AVVs) [309, 310] and Defibrotide (defitelio) is a 
combination of naked single- and double-stranded DNA isolated from porcine intestinal 
82
mucosa [311]. In 2018, the market approval of eteplirsen was withdrawn by EMA due 
to lack of efficacy [312].
In the clinically approved products, four main formulation strategies have been 
employed: (1) chemical modification of the oligonucleotide; (2) covalent conjugation 
to carrier polymers; (3) encapsulation in lipid nanoparticles; and (4) delivery using 
AVVs. As naked RNA is rapidly degraded in the bloodstream by nucleases, chemical 
modifications are necessary to improve the pharmacokinetics, pharmacodynamics and 
biodistribution of oligonucleotides. These include modifications to the backbone of the 
molecule, to the nucleobases or to the ribose moiety. For a detailed discussion on 
chemical modification strategies, the reader is referred to recent reviews [37, 313]. 
Drawbacks of chemical modification may include loss of binding affinity or potency or 
unexpected toxicity. For example, replacing phosphodiester bonds in the backbone with 
phosphorothioate greatly retards degradation by nucleases, but also reduces target 
binding affinity [37, 313]. Fluoro-modifications of the ribose sugar at the 2’-end are 
commonly used to improve pharmacokinetic profile and reduce immunogenicity, but 
may also result in non-specific loss of cellular proteins and hepatotoxicity [37, 313-
315]. This formulation approach alone does not allow targeting to specific organs, and 
thus, the amount of dose reaching the target tissue is inherently limited. Regardless, this 
strategy has clearly been successful as the majority of the products currently on the 
market are naked, chemically modified oligonucleotides in solution. 
For viral vectors, the main challenge remains to be the body’s immune response against 
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the viral components, which can render up to 50% of patients unable to receive AAV-
based therapies due to pre-existing immunity against the viral capsid [316, 317]. While 
additional measures, such as modification of the vector or immunosuppressive 
medication can be used to mitigate this issue, immune reactions remain a major limiting 
factor for these vectors, especially when repeated dosing is required. Still, the excellent 
transfection efficiency of viruses, evolved through natural selection, still makes them 
an attractive nucleic acid delivery agent. Nevertheless, the challenges encountered with 
AVVs and with the administration of free chemically modified nucleic acid encourage 
further development of polymer-oligonucleotide conjugates and nanoparticle-based 
delivery systems.  
Conjugation of nucleic acids with polymers and biomolecules can and improve stability 
and pharmacokinetics. In currently marketed products, two classes of polymers have 
been applied for this purpose: poly(ethylene glygol) (PEG) and N-acetylgalactosamine 
(GalNac). Notably, conjugation with GalNac polymer allow efficient liver-targeted 
delivery as GalNac binds to asialoglycoprotein receptors expressed almost exclusively 
on hepatocytes [318, 319]. Compared to encapsulation in lipid NPs, using GalNac 
conjugation requires more extensive chemical modifications to the RNA to protect it 
from degradation by nucleases. Alnylam Therapeutics has developed and patented a set 
of chemical modification strategies, termed Enhanced Stabilization Chemistry (ESC), 
which they apply with GalNac conjugation to achieve high stability and knockout 
efficiency [308, 318-320]. The recently approved givosiran and lumasiran utilize this 
platform for siRNA delivery. While this method is expected to revolutionize the 
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treatment of many severe diseases, the platform is only suitable for liver delivery.
LNPs have been used in several commercial products to delivery small molecules since 
the approval of Doxil/Caelyx and Ambisome liposomal products in the 1990s and the 
approval of Onpattro proved that the lipid nanoparticle technology is clinically relevant 
also for nucleic acid delivery. The Onpattro formulation is based on the use of a unique 
combination of lipids, including PEGylated lipids to prevent immune clearance and 
cationic ionizable lipids to allow encapsulation of negatively charged RNA, efficient 
transfection and endosomal escape [94, 321]. Essential in the success of this lipid 
formulation was the development of novel synthetic ionizable lipids of high potency 
[321]. Despite of the success, Alnylam is no longer pursuing the NPs formulation and 
focuses on PMO (phosphorodiamidate Morpholino oligomer) and GalNAc-conjugate 
technologies instead [37, 320]. A major limitation of Onpatto is its immunogenicity, 
necessitating concurrent corticosteroid treatment [320]. 
The perpetual efforts in developing LNPs based RNAi vector may also accelerate the 
developments of other commercialized products. The most recent achievement for 
LNPs technology for RNA delivery are the COVID-19 mRNA vaccines developed by 
BioNTech/Pfizer (Comirnaty) and Moderna (mRNA-1273). These formulations are 
largely similar to that of Onpattro, using a combination of cholesterol, structural lipids, 
PEGylated lipids and proprietary cationic ionizable lipids [322-324]. This platform is 
now being applied by BioNTech in several clinical trials for vaccinations against both 
viral infections and cancers. However, detailed discussion of mRNA vaccines is beyond 
the scope of this review. 
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7.1.2 RNAi delivery systems under clinical investigation
Selected RNAi products currently in clinical studies are listed in Table 3. Excluded 
from this list are naked chemically modified RNAs, mRNA-vaccines, viral vector-
based formulations and cell therapies (in which RNA is transfected in vitro). The 
formulations under study cover a wide range of drug delivery techniques and are 
discussed in more detail below. 
Several subcutaneously administered siRNA products based on the GalNac-platform 
are currently under clinical trials. Cemdisiran is intended to reduce the production of 
complement protein 5 (C5), which plays an important role in several lethal rare diseases 
[325] and two phase II trials are underway for the treatment of atypical hemolytic 
uremic syndrome and immunoglobulin A nephropathy. Additionally, a phase I safety 
trial (NCT04601844) is ongoing for combination therapy of cemdisiran and pozelimab. 
Several phase II/III trials are ongoing (and several have been completed) for inclisiran 
on different patient populations with familial hypercholesterolemia or increased 
cardiovascular risk and elevated low-density lipoprotein (LDL) cholesterol. Inclisiran 
interferes with the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), 
an enzyme synthesized primarily in the liver [326]. PCSK9 binds to LDL receptors on 
hepatocytes and promotes their lysosomal degradation, which ultimately increases the 
production of LDL cholesterol. Additionally, one trial in ongoing for the product DCR-
HBVS, now called RG6346, by Dicerna against chronic hepatitis B virus (HBV) 
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infection.  
At least two relevant LNPs products are currently under study. A saRNA product called 
MTL-CEBPA by MiNA Therapeutics is evaluated for the treatment of advanced 
hepatocellular carcinoma by in a phase I trial. The activating RNA, encapsulated in 
“SMARTICLES” liposomal nanoparticles, is intended to increase production of 
CCAAT/enhancer-binding protein alpha (CEBPA) with the ultimate goal of reduction 
of fibrosis and reversal of liver dysfunction [327]. A liposomal formulation of EphA2 
siRNA is currently under study at MD Anderson Cancer Center. According to a 
preclinical safety report, the liposome consists of 18:1 PC/DOPC lipids and is loaded 
with siRNA against EphA2, a receptor tyrosine kinase associated with cancer 
proliferation, migration, invasion, survival and angiogenesis [328]. 
Another interesting planned to start at MD Anderson Cancer Center is looking into 
mesenchymal stromal cells-derived exosomes (extracellular vesicles) for delivering 
KrasG12D siRNA in patients with the KrasG12D mutation. This mutation has been 
shown to be associated with the development of invasive and metastatic pancreatic 
ductal adenocarcinoma [329]. Several phase I/II studies are active for the polypeptide-
siRNA complex platform STP705 of Sirnaomics where the platform is used to deliver 
siRNA by localized injection to treat several different liver and skin cancers as well as 
hypertrophic scar reduction and keloid scarless healing. In addition to these colloidal 
systems, also a macroscopic siRNA delivery system is under clinical study. This 
LODER technology by Silenseed Ltd. is based on poly(lactic-co-glycolic acid) (PLGA) 
biodegradable polymer implant for local, sustained delivery of siRNA. 
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Overall, several technologies have successfully been used for RNA delivery and many 
new approaches are under clinical investigation. These advances have already helped 
many patients and vastly expanded the range of treatable diseases. However, major 
challenges still remain in delivering RNA to tissues other than the liver through 
systemic circulation. The development of advanced, targetable colloidal drug delivery 
systems is required to enable efficient delivery to different organs and to expand the 
applications of RNAi therapy.  
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Table 3. Selected siRNA and saRNA therapeutics in clinical trials.a








Hepatocellular carcinoma Liver, intravenous I NCT02716012Lipid
EphA2 siRNA Liposome (DOPC) National Cancer 
Institute (NCI)
Advanced solid tumors Several organs, 
intravenous
I NCT01591356









Metastatic pancreas cancer metastatic cancer, 
intravenous
I NCT03608631
Several liver cancers Liver, intratumoral I NCT04676633
Hypertrophic scar reduction, 
Keloid scarless healing
Skin, intradermal I/II NCT02956317









Polymer LODER technology 
(local RNA delivery 
platform)
PLGA implant Silenseed Ltd Pancreatic cancer Pancreas, intratumoral 
application
II NCT01676259




Liver, subcutaneous II NCT03999840
NCT03841448
Inclisiran / siRNA GalNac conjugate Novartis 
Pharmaceuticals, 
University of 
Oxford / The 
Medicines 
Company 
Cardiovascular disease, High 
cholesterol, Homozygous 
familial hypercholesterolemia










DCR-HBVS / siRNA GalNac conjugate Dicerna Chronic hepatitis B Liver, subcutaneous I NCT03772249
a RoA = route of administration, saRNA = small activating RNA, DOPC = 1,2-dioleoyl-sn-glycero-3-phosphocholine, siRNA = small interfering 
RNA, , PLGA = poly(lactic-co-glycolic acid)
89
7.2. Adverse effects of RNAi
The discussion from previous section suggests the adverse effects and toxicity is the 
prerequisite yet the major obstacle for clinical applications of RNAi. Among the most 
pronounced side effects of RNAi are the off-target effects and immune stimulation 
[330]. Off-target effect is the undesired silencing of non-target genes expression [331]. 
It can occur due to the non-complete homology of RNAi to target mRNA that can result 
in partial binding [332]. In addition, coincident sufficient homology of RNAi (11 base 
pair) to other non-target mRNA can result in translational suppression or degradation 
of this mRNA [333]. Off-target effect can result as well from the loading of sense strand 
of dsRNA or miRNA (equivalent to target mRNA neuclotide sequence) into RISC 
instead of anti-sense strand (complementary to target mRNA) [332]. The improper 
RISC loading orientation results in neglecting the target mRNA and instead silencing 
of unintended transcripts complementary to the loaded strand [334]. Consequently, 
regardless the depleted effects on target genes, the off-target effects can result in knock-
down of different gene expressions and toxicities with major consequences that can 
level-up to cell death [332].
The other commonly observed side-effect from RNAi is the immune stimulation. Non-
specific administration of exogenous RNAi can result in the activation of innate 
immunity through the induction of interferon responses. This can be induced through 
binding to the cytosolic receptors; protein kinase R (PKR) and 2′-5′-oligoadenylate 
synthetase, which recognize long dsRNA. This is in addition to binding to toll-like 
receptor (TLRs) family (specifically TLR3, TLR7 and TLR8), which are responsible 
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for recognizing nucleic acid on the cell surface or in endosomes [335, 336]. This 
induces a molecular cascade, which leads to immune cells activation and release of type 
I interferons and inflammatory cytokines [337]. Although sometimes the immune 
stimulation can be a serious adverse effect, it can also be beneficial, for effective 
therapy against cancer or viruses [330]. 
The design of RNAi should be carefully considered to either avoid or induce immune 
stimulation, according to the specified application. Although dsRNA longer than 30 bp 
are known to activate the innate immunity [334], some shorter (>23-bp) dsRNA has 
also shown to induce interferon responses in some cell lines. The threshold length of 
RNAi may vary with different cell lines [338]. Specific sequence motifs, such as 5′
GUCCUUCAA3′ or 5′UGUGU3′, can induce the production of interferon and 
interleukin by plasmacytoid dendritic cells [335]. These motifs are usually U-rich, 
which are difficult to be eliminated from RNAi drug candidates [334]. In addition to 
the immune stimulation, systemic administration of RNAi can result as well in non-
specific distribution to non-target organs [339]. This would lead to gene silencing and 
toxicity in these organs, in addition to increasing the required dose of RNAi [340, 341]. 
Further unintended side effects may appear due to the saturation of cellular RNAi 
machinery by the synthetic siRNA. This will interfere with the gene silencing effect by 
endogenous miRNA, and finally results in overexpression of certain proteins and 
induction of toxicity [342].
The undesired side effects are the major obstacles for the successful clinical translation 
of RNAi. The first clinical trial with siRNA was on bevasiranib for targeting vascular 
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endothelial growth factor in age-related macular degeneration patients in order to 
suppress ocular neovascularization. The clinical studies were terminated off after 
reaching the phase III trial, because the medicinal effect is not due to gene silencing, 
but the non-specific immune stimulation via TLR3 activation [343]. ARC-520, which 
is a targeted anti hepatitis B virus (HBV) siRNA with promising therapeutic effects, 
was among the first antiviral siRNA to enter the clinical trials [344]. Its clinical trial 
was terminated due to death in non-human primates induced by administration of the 
highest siRNA dose [345]. MRX34 is a liposomal miR-34a mimic for advanced solid 
tumors, and was tested clinically on human as the first miRNA cancer therapy [346]. 
The trial was discontinued due to reported severe immune-related side effects, 
including severe cytokine release syndrome [345].
Different approaches can be considered through different stages of the development of 
RNAi candidates to eliminate the off target effects. Among these approaches are 
sequence design and optimization [334], chemical modifications [347] of RNAi 
candidates and development of effective delivery system and targeting [345]. The 
design of selective and hyperfunctional RNAi is a first step toward the reduction of off-
target effects and short-list the potential candidates [348]. Bioinformatics tools can be 
useful to avoid the design RNAi of seed region that is complementary to off-target 
mRNA [334]. Additionally, an important factor that should be considered while 
designing RNAi is the sequence-potency relationship [334]. This highlight the 
importance of developing and advancing bioinformatics tools, as it is the first step 
toward the development of effective RNAi. Screening the RNAi drug candidates for 
92
off-target effect is a helpful tool as well to early eliminate the non-potential candidates. 
Protein array technologies will help to provide a representative image about the effect 
of RNAi on cellular protein expression [349].
The design and sequence optimization of RNAi candidate is important to reduce the 
side effect; however, it is still not sufficient to totally eliminate all the possible immune 
reactions toward RNAi. In this regard, different chemical modifications have been 
developed to enhance the performance of RNAi and reduce the immune response and 
off-target effects and enhance the guide strand selection and delivery. It is also 
important that chemical modifications are not adversely affecting the potency of the 
RNAi or impair its pathway. These chemical modifications can be classified as 
modifications phosphate backbone, the ribose moiety or the base [347]. Among the 
commonly used modifications is ribose 2′-OH group substitution with other groups; 
2′-O-methyl (2′-OMe), 2′-methoxyethyl (2′-MOE) or 2′-fluoro (2′-F) [337]. 
This would protect siRNA from ribonucleases, which require the 2′ -OH group to 
hydrolyze RNA [347]. In addition to increasing the resistance to degradation, this 
modification can reduce the risk of immune stimulation and decrease cytokine 
production [350]. Modifications can be performed at the termini of RNAi, which are 
recognized by immune cells. For example, siRNA with added 3′ - UU can reduce 
immune stimulation and enhance the gene silencing efficiency [337] .However, 
modifications at 5' phosphate of the antisense strand cannot be easily applied, as it is 
essential for recognition and binding to RISC [351].
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RNAi delivery systems should be non-immunogenic to reduce the side effects and 
avoid excipient-induced immune activation [345]. Additionally, designing the delivery 
systems to provide time-controlled RNAi delivery would be beneficial to control the 
intracellular concentration of RNAi. In turn, this can reduce the concentration-
dependent side effects such as off-target effects, immune stimulation and saturation of 
the endogenous RNAi pathway [348]. Tissue or cell-specific targeting is important, 
especially with systemic administration of RNAi to avoid gene silencing in non-target 
tissues inducing unwanted toxicities [352]. Additionally, targeted delivery can increase 
the therapeutic window of RNAi drug and increase bioavailability in targeted site, while 
reducing the off-target effects [345]. Targeting ligands can decorate the NPs surface or 
be conjugated to the RNAi itself. Among the targeting ligands as mentioned before are 
aptamers [353], antibodies [354], folates [355] and N-Acetylgalactosamine (GalNAc) 
[319].
Ultimately, different strategies should be combined to reduce the side effects of RNAi, 
starting from the careful designing of RNAi sequence to designing an optimum delivery 
system. For example, Dicerna Pharmaceuticals developed Dicer-substrate siRNA 
(DsiRNA), functionalized with GalNAc moieties. GalNAc is a ligand to the endocytic 
asialoglycoprotein receptor (ASGPR), which is an endocytic receptor overexpressed on 
surface of hepatocytes, and barely on other cell types [356]. The ligand moieties are 
linked to the tetraloop hairpin of DsiRNA, which is connected to sense strand, constant 
sequence, and antisense strand composed of a 21–23 nucleotides complementing the 
target mRNA. The design would make it difficult for the sense strand to be loaded to 
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RISC due to the constant complementary structure in the siRNA sense strand. This in 
turn can diminish the off-target effect mediated by the sense strand loading to RISC 
[347]. Finally, different adverse effects of RNAi and the potential approaches to avoid 
such side effects are summarized in Figure 20.
Figure 20. Schematic representation of the challenges that RNAi faces and the 
sequential adverse effect, which can hinder the clinical applications of RNAi, in 
addition to the potential approaches to reduce these side effects.
8. Conclusion
RNAi based genetic therapy provides hope for intractable and incurable diseases. Non-
viral RNAi delivery systems have drawn increasing attention in the research community 
due to their advantages in safety, controllable physiochemical properties and economic 
feasibility. Challenges, ranging from NPs synthesizing conditions, successful RNAs 
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encapsulation, protection and efficient yet precise targeting capability and efficient 
endosome escape behavior, are potentially laid ahead to achieve efficient therapeutic 
outcomes. Understanding the potential mechanism of each step is the prerequisite to 
properly resolving these obstacles and, as a result, the recent advances in utilizing 
optimized NPs formulation has enhanced the RNAi efficiency, and expand the 
application scenario to a more broad area. Furthermore, the continuous efforts may also 
provide fundamental knowledge for facilitating the development of other nucleotide-
based new cargos, such as self-amplifying mRNA, which holds promise for efficient 
next-generation vaccines.
However, further knowledge is still in demand to better promote their clinical 
translation perspectives of RNAs. From a pharmaceutical engineering point of view, 
the major challenges come from the issue of variability and reproducibility under 
laboratory setting [357]. Diversity in materials choices and detailed handling protocols 
from different laboratories may lead to inconsistencies between different studies. 
Further exploration of the underlying mechanisms of nanoparticle formation and RNA 
encapsulation remain paramount to achieve consistent results and enable rational 
formulation optimization. Meanwhile, the development of modular NP production 
methods, such as microfluidic-based production or continuous extrusion, may also 
reduce the batch-to-batch variation [93].
From a biological point of view, previous studies demonstrated the potential genome 
alteration as results of off-target RNAi delivery, also suggesting RNAi may not be in a 
traditional “dose-effect” relationship, where a conversely upregulated target gene 
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expression may be induced under high siRNA or miRNA concentrations [22-24]. 
However, despite the advances highlighting the increased RNAi efficiency by using 
NPs for intracellular delivery, a systematic investigation on the concentration 
thresholds for NP-based RNAi, and the potentially induced genome alteration with high 
RNAs dosages is still needed. Corresponding investigation may bring fundamental 
knowledge to the whole scientific community and facilitate the understanding to the 
physiological barriers of RNAi, thus holding enormous value for achieving precise gene 
therapy.
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